var title_f4_56_4992="Ross River virus generalized rash";
var content_f4_56_4992=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77070&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generalized rash in Ross River virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 244px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Some patients with Ross River virus infection develop a more extensive, generalized rash which can be vesicular or purpuric.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Richards, MB, BS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_4992=[""].join("\n");
var outline_f4_56_4992=null;
var title_f4_56_4993="Cafe-au-lait macule";
var content_f4_56_4993=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large caf&eacute;-au-lait macule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 326px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFGAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDxDw3ZBwGdfl9MVt6wFigIVcsemfWrWhWwjtkIADbcdar+IctEcH5RyB7CmDldnnN6drtnqSc59ataIvI4yeucZ/OqWoEgheSCc81u6BB+5VjyW9/yptmh0OnwKdjdMc8D9a6CCHAGE+XOc1Q01AfoMHA/lW1bjIGfmPb61mSyWKMAruPAGDVyAcDIyQOhqKFCwU5zk+nStC3iL5wBgenWgkZu2OAVyee2cGp449y7guc9vUVLHbgDeecHkZqbB4C8HqKQ9OgyGIghcknn3zVmOPJxx06AZxT41RRhse4z1pwBCgYH1A5xRsJjUXGCzcZ+pqW2kBOVCqwOfrUbEgEsGGT9fwqSMFBluAe2Pyp3CxZySCWBIBx0pbUBpST0+n+fypqNuUHlewGSeKljBDDgAHjp05qtxWtoaABKfMfcE8D9KdwQBuO3b25qKJmPGS2OeO30q2mBjJ56Yx+lF7k2sRmErGXUEjrvx1pi27P95dxwOf6VdH3SQgYA84P+c1NH5a9sknucUwcmQJEqJucDgZ4NWIyj4EYOTxkfpTmwQMntgADofrTCwXODu7DnipbKjEsJgKCvLHjn6fzpC7NtG4nng9DSRrkhmJGO1TpH0Zeq5Iz2pFWsMER2Fjx349ab85fgZYd+1WmU5BwOu7rzUBcGbyzuI3Y68D3poN9hNxJA3cA8DHWraLtJyELDnHrTpIMopzg5PXvTFJjZcg5x0I6UNlxjcuRsrPgYz1AFSHaBlTjcfTpVKIkSsoJb1IHIPtVqMAjIGGxgkD2qGzXlsOWQ5C8EjOSDyfwoELbR99uO4wM0kZGTgDt0OaugZBJ3A/XOD7VKFLQyHiYEjO05HvT48q2XGfXHYVakjwFOeRxkdD60+3hDOCQ+3BGcU2NSIVdl2qrDjvzTH+ZD5kmD7c4q1KnGGAGeoIweKhQMSV/i64B4AqWUrFRsA55A7ewJpWRz8w+Ud8nqPpT5omUOeCD37VGG2thQpI6g9aRfTQiMeFJAIA9sHNZ12xXjJIPUY71pSt5g+TI9TVCaM+rEdx6VLZS7szCxLEsRlhx82BippH3Z428cY/z0pskZDNjueMen1qObhN2cHkde1O5UrMbMu84AZsH07elQzR4HI6gLxzk0K7btvBAHU+tK/CpsPPBIzTI2ZVbnK5Gfpz+H4VHJGrNkkhfTPX/69WOD95gepB7j/CopyQGIyAOcDntRsF9dCpNGNhycnnBA/DFZksWWGcKpOeOcj2rTdmOANu0jnpVG4+vvyP1oBXMq+yRsHzLu+h/GsiZgJDuC59+a3po1Zgc49BjNZ00ZDnaCfU5p+g00tGYNiirbqo7jsKyPEDho2XBGPStqBcRKCNp/WsLWdpT5Bn61sectzz3VObsqoPHABrrNFixFHg52jFclefNqTDsGxXaaKdqoFUKMAZIps0OjtU2oFXJJPNbNsmMEDgH5RnvWdYIVYDG0nvW1bJlSOCoxk1Arli3ABG4f41oIyo4U4zyfwqCNVEeG9Tj8qniDbxu5HrR0I3LCxk7SSMdQamEeDjAyOhHakBX0wR0FHmcHaevc9KNgu2LnPyqv405MsowCAOvbioEbgbjhQOn9atRMW4GCWA5HAzTGyWOPceQNoGSf/rVMqblU8HOf/wBdMjBDbepJzxVpBtI3qMA9+1CJbInQBlbAJOR0xT0TJyQexBNOd17EDPIxzTFlPAYcelNDWxdjQKc8Bun1q7G5T5eueSSetZ0Mu5h069c9KsRszbQcsOuO2aaIky2gDYZu3QHtTmjADHdx7DkYquGbaScev1OacjNzvJ+bj6fhQ+worUky+/aO/X61Ip2yfMQBj/IoiC/L03cVKwz0UHsRjg1Jsn0JUVGTAG4nPOanjXgclT16VWCtH12ntwP84qwr7Rnn0GRQOxNwD8yjGecio4IIkkYouMksM8nJpm52IBGDnpT7XGQSSAD09e2BTBF1PmJD7iSASSP0FOljBABGc9Seop0aFjkZPfAHf6+1WCu1eDkYzyKllrQoi3wuGywToQfyqQKCAwPPscn8amcMe+V+n6f/AF6UDG0KFOD096m10ac3cFjRcE9BkAZ4/GpBIeqsQxO3j09aeFUZGQTnkelOEDA5+6fTPH4UrEtkTgADAOByafCQitvJXC8gn+VOnYDoWHqc5NVWlBfrgnrnvTBItO4xgbDlRgZ5FQgLvBK5OcE9h6VGPmkG05IORn06VI6kPuQNnP1IqGjRDJm3AKNpOM7ugrPnAdj8yn3q7cFdrFjlSMMenNZ0oL5wSMgdOlDKiNIJBAB5Hf8AlULK6x5b0zj0qRmKZz25xQ0iuD0BxweuaRTZl3ZKSDkbicZxyB71TuW+Zim3Ptkcd60rnDEgDLdcH0rNuIGXAUkZzj65oSKTKyHDEtyo4okO7lvut19aSUlSSQASMkDk1WaQAhWOGAxkn9afQGrlhlBznac84xn8sVVmkkUZ78AE5xStKCOH2r7HpUDy7j1HXH/16V7iSI7lhtHX8v5VTnwrDJznoccipp3PHIyep9aguOUG0kjPpjigLWM2eQq3Tjqv+NUJWO8/Pt9sVdmG/OBuJ4B9azZ02yYYgn3FUh6FDISIMOCOuK5vUTlnJPIHU9q6afG3BHPauevgCrtjGT1Na9TzUeeyfNqnTJ39MV22i4wFOQ3tXDgltRY993au50MfKgAA45z7VUtjU66wA8lWU5GeK1oAAQSCO/TvWbp/+qAz79O1asJVlBGcDpzUWILluV2YGGY9CBipQSRwDzxwagEiogJIwewqubpQCFYjHfvRdCtc0HlEUY8w89OKryXjduABn8KzLi48xz8xJNMhlVUI5yeB7VDkXy2L8Vy5HJOAfzFaEN2VC8kP2z2rIhPybgTuwMN6VethwOevrzU3CSRpi6dZAcHJ/I1It24TlmOB9B+FZ6MCcYyR3P8AKrHI68YAo1Jsi3JdEKvYN1ApRd4IABP0HWqHmnGMjIPbuKa4bAZSRjvTTY7dDdt7hMgLjHv/APXrTgmAI6bj71y9uGIByTjnHpUxeVQMHO5uD0/GrUzN07nT+cuOg9B7+/tSBiAMHJxzj9KxrW4KjLfM3oRV0XsW8AYABOcdDTcrjjG2xsxgDDEk9CTnrVqL7oK446DPNZcd9GFQEKcDr1HpVqK9RVDE4b1NJyRXKy4VJGMgg9Sf89anWNgGDdT754I71Bb3EeV4GPT0NWZLiIqMkdKLhZoiCZbc5HAxU8QVsEk7lGQM4qjJchH4PJ5zin20gdiGyAD17g0c62LSNy2facHGSOegwfpVhzhQcYBHQ81BbhcE5H09D6VKQCwVT19OnbvQ9RpakahidwUNzklmprg4cA54zgn9KsNtTkc7h1GCKQKONuXGCenU1PMWhkakE7hnPLY7ewq/EgdBnIAwSfTjj6VUZR5gxyBnPPSpY5goVRtJHAY9PoaNxPUbNGS27nHPJaq80APz7fvcDcfzq3Kw3nkAqMj+mKDHvj4xkfeDDGD3oHsU1Ow84LdMe1PaQLgHb8x455HtSTwqj89ucGjy1JYv8rcY46UmO6Kcw3fOF4PYcVSkkCHA2hSCDjkc1ruIQo2nvkc9f8Kx7yNTN1OAeADjtSt3Li7jD8yjd0J6YJpGTamF5I6jHNDrtAw24g4z0/A1A8pG8dSP8/lSsVqxs+EHbHYetZ1zIF3HgDPPPSrM8m7OW+YdB1xWbOS54J4HTtTHGPcqXE/y4HVs8gYx7CqTthgBjnkZ71PMSW4H5cfnVaYh2JPU46cH2oNrWAxFgSexJPqKRo2IIz6HrjFPjYsoHB54NDHjcSMdD9KCG2QshKgsfUjjFVJ2XYBwAf1rRlXKnn061lzoA4znaCenFBCaZlyuVOBge/p7fWqbyAsTz+dX7tdvTGO3+FZEpJbPA+pptaF6PYp3h2ooHTrWBq7+XbNkZwCDW/eEeWcjOe56VzPiNhHp7gEZKk/X61qtzzInC2CebckZ+8cCvQNIGGxjnHfj8q4XRk33A45zkV3+kqCgPQngEjrVSNGdLZkbSCcHjBrSR1iQsOT3xWZbsI0HQt1waldxsXPBIzjoKyk7CSJmcu5JLbDyeeKikkIj4yCfSkLYXOcDj5fWqzMxc4PX161maIe8hyCcGpo1DMCP4uagQjtk8cn1qdGAYLyT1FPYTL1uoyEPA571fh27FOOMce9ZkZLPlcEehHFaMLZIGBgHJB7UEu5ZiG3A+8R2p5UtgAEnnimjBTpg5yfapV7DgKBnH9aBbjUjG7gjPUH2qdYxwduc++D9KSNMZY4GPap2jJG4kHB6A8VLLsGAFPf+dNI3DgEc8mmxIxc7uQemRVoIAoXGABj0xRcHGxWUMSWzgHOP8/1qRUJYbunbjirKRJuA6ehHOfwqQqGGMAk9we9DYRJYo2J4GcY5q1FH0GSABnI9ahhYsMBSRjsOpq1bZJ79AO3+e9TcuxYZvLGFGT7etMW4cq2CBt4yQeakkQlRklv1NQwwcJxz0GP5UrjSVtS1bN5jDknnken+NWCAvKkc5z/ntVaKJoyDkYHXHH4VbhdT3PP4Y+tO9xW10L1nctGRl+O5AwPatO1lDj5iN2M8jpWMjbTlSAP4h61IJSsnybt3vxkU1Kw+W5vIglbGWByMEDAJHvVoxZySRyc8iuaivZETkkjI+90FXYtSYsFbOADx39hTU7g4s1tmMkDYOFJ9vT/69K8YAbYFx/FkdR6VUS9SQgjtyeauxkMyFe/IAAqk7kvTcgTaGClFYHp83T6VO5wg9CcNj+tPkiwqlsAkkMQTmqtw4VMKpJJHbj0pi3K9wxBKlQAe4PSojJ1K4/LNTHLucF89gKRokDhtoUYwAPUU7lJWM+5VtxUBvfA4+lQKjkln5HT6f/XrTkRSx2AjB46c1FJFtG1eTnt0qSlLQypU5yT0PGf8Kh8v1GT/AHe+avzLtHzYA7d8etMbIiJBOcDvSuVzMypUXKlsD2PH+RVWWHCEDBIGOeRn2rSmJXsfYHqKy5wWwOS3UEd//r0Fx1KLoADtGBkdulUZE5LscjOc9wK1JDiLaRhQetZlw2Jemc8fX3ouXErgkPtOAOe/fFKTg4Cn35pzZySPfJAqFWVcpwML0B6U0OWoly/QAkgcjnOOO9Zs8rsSGznj8quzHO0Ic+tUp1ATkEAZ6HjFO5CVircKSoGD0HG3FZc0LeYcEirpfHfPOCM1Ukky33AaG0NXRiSTs4cYwO2eO9ct4xlK2RU8ZIrpRG3l7i2QePeuO8Yv+6C9y2cVrHc89bmb4cUNKc9FIPPQ13+nINiHg7uue1cN4cjG/GQcnp/Wu4sZERtoPIHU/wAqcvMb3NIyEyLuHA/zzVuMFo8tyD2BzVKIAy5bJ+bmre8RgKuAPQ+lYvUpbAWyT6r0xjmoSSQcDnHU1KhPzEnr3A6VBnkseOTUlDlY4yDznirEbBsk4J/UVURuo5IHrVqMbWw319qBl62GBk9G6VpW6FUzlj2PHaqFrncM9PZelaULYIPIHH/66LkSJEQj5jlT6nnNXY1G0HBHPBPao0RRt64PX2qaLIJ+bA7ZPb8aVwSJIB+8Krk846VYaMMjcgHgcdRUecbcbT6AjtT3cGPBPIHb+tJlpDo1QPngr6+tS7QGyMMcY/D2qCFxu2ufvHqRzV1uFLLztOBjuKm4SRFn5QN3zNwTngU5VVW5OW5+X8aailgSEIxyMDirUVuc8txmmyY6MkRd64O7I9O/+ealXII6A54/z61LDGCueRxwMVK8QQ5GSTUNlrsMLFwuSABj6gdqswhDwDk9OD+tVwmcgAnNOVDu+U4H+e1K5dixNg8njHr+lMjPzeo/LHv9KCDgZzkcn86eiIW+U4GelFwLAbavGPXPTIpjS4baNxx6f0pRgKQeAOpp6xhiRzkk/wD1qLgiCORm+9g+o71Z3AIf7xHUDqKY8K4XK4YfxdDTcMI8Z/AUJl6PYmjn8t9wcDBz/jVmPUHQKqtnPpWayhSDjkHken409UAAHHPHP9KdxWN+LUCUCknBBAJ7fSkE6btu7gnANYwdgoUA5xjH+e1PEuDtBPbJHH6VaqMnl7G7HhdrHIAOcZ5PPY1JIjs2F+Y4OGxWTbXhUc45/lUzXyhdvJx6HP1xTciS3kYXJBxjIxx/n2qKQlVxswoz9aqf2j1BIA5IAHUVD/aKSPjkg9RinzIOVsdcuQ3U5474qo7jaRx8ueasPLGyjHJyBg1TZVLgg5Iz/nnrQaRRWl3MRxnnHWqM3yNuCnHIye/+FaIAYEjbnqcCq80DsBgc9DntRsXexR2ltzLnacjOOPb9azpVVpCMAZPU9K1zENgDA88cVnyx5bIOc+v9aBp6lGdcJ3x04H5VRuNyKc9c9uTVm5DFyMAYOcH09qqiGOIyGJFVmbexHVmwOT+lNFbFYl2U4U4zjg/rVWdm2mPkmrm0AZPynPGBUMqHPKgA89O1NCbMt0ODzkH171UkbLklOT+GKv3KBkIB3Y6896zZYzu5J9hz0phe+5l3ShLYjqBwfWuB8XEEoO47+tegX6lk2jIDc1574qbdKAo+UNjPrW8dzzo7jdEfyoZDkZJwPrXRWMoRlYdcHnvmuYsmH2VNuQu/rjp710mmK3y5TJzk9qmpuaJHQ20jEAnGN2DxVtHO/ByR0H0qnAMR5Uc4INWv4FI5AGCfWsWMUkjaBjaQelMcgMh/Kn7iAQ2GP3RniomUYGV4PANIZIo3YPGCKtQDdzjJHtVVOAAMYP61bhyq8dP6UAadphTlgSQK0YCh+YEbOD0rNgZGHzA4B6e9XYH2KBsHHoe4pE2L7MOB8oB54qeJid3PJ4BAzVQDfzjt371dto+hYD2BpFpJImiQnlzgHnJqVR/fHByMdiBUinIHTJG3gelWoo92ApwD69/pSHcrJbLu8xRyw6DJ5q9AAFxtwPUng/WpFj4+ZRj72D049KmSMZHAwx9M4/wpWFKV0VcKh+XHHOatwLkAjk+3P51E8PIPRuoI649auWUQ2/Kuc9h/WmyENdAjfL7d6GIIADFc/wB7uParbgFRtJJ9BUQjDKR1JzyeazaNYkUJVR/tZABPQUrkOx5+XPXHf29qd5WWxzjt/nFWI4yACACAOlJlCIrY4xknGc8/lQAM4wM9cetTQZQ4HPGPc0jp+8HycAYwDjP1pAMCgkAHKntUiw7VG7OT09hTgjfKOCR/CetIXZQADkY4HvmgBrnBwdvyjj6UyTOzAOAMEdqlRGb73Q96knHydM8dc/rTvoWisGzkq3HoRj8qA2QcKPYkYzTSGwckZAweeo9amt4yEViep4UcikinZEDFgc9yOc+tPAIjwQW9l/OpmQFc4HB7dvwpuDkuMADIz0qtjO9xnQDnOeh/xprE7gTnAJxVxUOF4AXpgiqzIduOh7DHX2obBEE0hB5PykcHPSqchJ+7kEgdOtXHh3Zc8N6jnFQSRtkjjjv9elK5rGxAs0jEqSRx24//AFVKZ2VVCjGBjb9aIoQGyOWwKimJB4wH7YxQm0N2ZPHKWbBIxn8sVf3fLuJzjp7+9Y8LtuG3aADnrj65rSGAMA5x6Y59s1rAiasU78AdFbj0rLcEtypHORk9a1LxduSYySO2azJvlAJ+g9/xqkC2KFxFgOX3fMcEbun09Kz5s9ugx3rSm6AbjkdAaz7gfMDgnjH0plJlSZlRsA/r1qpLNuA+Y/7xqzPFvJwBx75P4VQlUhQAMD86aKSRXlfYNxIPfk1lyT/OeFP14q5fH903J4xWL8xJwGPPahuwJJli8UbiI+h6+1eceJV/0jPOOcV6ZqJJ3MvDY4461514iTLOSc49etdEdzzIFGw2tAq453/e9a6nTdyxjcOQOh5rldNbZByeCQK6nTvmVT0IFKZZuw/vAvVeMCrSqMY6596p2r5Ub+NvHNWmOAeMdOR6VgxoeMFRtzzQMHgEmkTnkkYHAGalI/dk9CevHFDGMjXJUYwc44qzbjDBemeuRUKcgDH4VaiUsvHpzkYpDuW4gWAABIx696uwQuWV2bGO/Y1XtQ2DgZI6DvWjEeQOfxpMm9ti3bgKh7gAgiraAngEYI6+tVYyWwFA9sfeq7EnPUnOOaVhplmADjCgEdcGr0PGATwOnFQRLtyMngHbmpge24/TPJzQCZaj+aTHA9Mc5qxs2xgEDg8kd6oRsFGPTjmrqNvHHAPAx64oBj4o8sSNpJOeasIM42jp2z0qEdj0bpmraR/KQOcDHXvQyEIELgD5gOxPU00Iykjn88celW9pjUEe/XqDVc4RgcfN6jrUaG0bsaYiNz4KjqPY+lT7Cy/NnGMDnv6Cmeb8oCqQT3B4pwkKjBG3kj5hjj2qTSxKVAIy251HXHFRMwZwD8pH8Poai83IKpwPUdfenLE3ylsk57n+dBVrbl0glSBhWz0HcVAcx/K4wCCOnbNTRMBlQMnpjNNljJO0fmTmkT6jUkCkjBA7YHANSMgIYMcg9MDr6ioY0lC/uthYdS4IX9KtLl4ULbVfZlgCWH+ffFIbdioy4IHUjqvWkV8KSc5Ydx/KpDGzlApLDrzx+dPEIAy/3Rzyc8U9tRbjWOI8EkDpx61GGBVgWOep9AastCChYZIAz6ZqADZkMRz6Ci7CyFUgDDH5u2DUc2BnqWPOBT7hW2ZQAAc4FVXlJGCenT/D3pBFEgcBejD9PrVG45LD7xY55/pVmMho1xkA+vaoplO04456UXLWjKhk2qVxgHv1qBSzuOwBPBFSyjyyeEOewP6fWoAq8ZIxjg55+lMof8sYLR8AjnPNPjugqkORk5GDVS6bCgH5WzzzVdM7uuEJ5HXPvTTsK10aryI4+8M9cjnHaqcqEuzAjb1zVVJSrjjIAycd6WG+jvbWKeMSBHB2+ahjcc91PStou5DVtiC6wAx6knjn/OazXIY46r059atXLlm2qTjscc1RlBVskDjnr0qi0tCBxjO0k/X/AA9KoXXbvnp9KvttOBJyfy4qlcnLHaMr64x+FCKW5nTp8jZ5zWXKgDfhnrWvMMDYT06c1j3Ct5h2lvwqkVEs6om2Jgx5/lXnniRCSS2M5BNelX4G05JJPYV5/wCIk3O6kgZGfStU9TyonO6eCYG9jnHt6102nMHj27jg+lc1Y5yygkY5/Lmug0w/IvIxjAx1xTmanRW4G0g5bHbpV6ErjazfKe9Z8BPljvng1fQY2ckep71g0InC4wT8zA8gU5h8nX3I/rTYwHBJJ4PUjrilXBbvUjCM7WXjnsD2q/b4Oe+TVZF5wDx34q/CANuM7T0oBssW+VPOdo6Amrq5wD079aqPlYiwAPOOO1TWrs8eHIB/pSYkrq5p27DAzjHXOOlXo2YYJyeeTWbAfLBDf/rq4h4XCsSOh6ZBx0pDsadu+QDuwPXHUVNnAbqPrVGLHXBHPt1qzGcDjjH50XHYsq2AueTU8TKCNx+XGagBAAK8Oo5NTQDoowN2O+c1O47F+FUBUE8cdDmtCPdtQZUnkjnFZsO7fuJyc5+tX7dt7Dk8EcH+lDISJn3EsV+6RgFv8PWq8sRBUKBt65HNXi6hFK4yCevSq8pI4GBkYO3oPpUtG0CqqlRnrxwfWhowzNgE/WgjB6H8frU6ZJbqOPu/40jbbUbFGi438gcgKKlUsQNvy45z/TNQuMOOyk9ByRVq3UHA65GBkcZpCbIAreZ0BHcZ/Spo3U7UPoeMUTxdWzkA1WXO4LkDGe1FhbkocDhlBXGOM1ZhlVl+YfMp9f6VXWMhGABP48URxsGJJKjuc5OPajYLXLOGJbGQqnOOmfapFAKngkZ6dKij5UFgCuTnB6U/YcDjjPAB/wA+1JiHOVYEnpjJPTJqq8PzEKDyehwKsshAJOBx3/z9KgVjnaDjoSM/yp2BETwvsAwBnofSq4hLuARg5JJb0+tacgDxlXXKkc9uPwqnJa7ZU/f3DBCGEYYdfc4zj2pblJkQiZc4A4z1PT3xUMzkFlcEk8Z6mrTMmflAOD16AVSkG5gAQO+SetMLFaaMksU4x1OKpyK/zNjjONuetaRDbcdSoPP9agKZByDuxjOetMteZlSxSEegz09cds1Acg4Ixj05rWONowG4PPqPes66hJUHkn0PShWC99GVp/lAJyD1wOoNUfN2zhudw6YqackMVHPbcO/+FVZWETZ64x1NUmNaE8jFlY7QMj09KqTsSB69aFuxs2EgnOMk9aWUhlyBjPQr04rZNPYT0Kblg4LEde57e9UpyScnIB4PerspCoWPt9M1mvKw47jkZ4poaIJzhSCpOOcis6Yhnyo4Iq5dkkfNyB+H+fpWe2d3GF+q0ykjR1FMJgHgVw/iBMsAASf5f54rudSwYycZYjA56VxPiABX4ByAMkA1qjyonJwjDSjOCQe+Oa1tPYJEqAZLDINZ+wNcSA8Z+Xb0q/ZEBkCg7l+X6Y605mqOottvlgD5SPSrqyBlGNwJHI/pWRaSlnVevGTxWpG4AUZwDweOSK55CSsWUJWLaMg9OKjgZ2kZWzwcCljbKnBxjpUkbDrznPp1pGkXboWwQqjOOferUDLwdxyemaphzgMcf0q1FkYA+nPSkTYu+YG9Ovfv9akgcLKcnGBjOKgQcZPckU9SBOCR1PvSHFLY1kZ8ADr1JIqxFJkjDHgZI/lVZUI2svU9M81ahGH42+9SItQvwSB8y8jj9KsRuxbADcc7fTNRBuDggYJ/EVLEM43dOuT3pMaLdvy2AOo57Z+tXYiBGSW3E8Z71TiXYQQM+xOc4qwcnlRlD6cY96YPUvWwDgcYDHPB61YVioAw2faq1s2EIJz2/KrkKHJOM9uKTCOguGz1+mKWPcFB52jI9Mn1NWQvzAhVAxwcYBppizj5S3GevWkaxdyBgzZKkkE8A/yqwqEL8yggnqeopgTCqMEJzxnOKsQupJwSDnJz296VzR7A6MRjbuA4246n3p6LtQlNu7puPc0yR9x7LzkEnFKjsSpDcDnOOppEDpSzIcLk9MHuO1MVNmCeM9CPzp7ZTscccr1FMlX5CDk7jnb70rlJEvAAwQpB6k55qv2yFwCcYGePSpY9xBVmyPfmlMgXGW74yBwTU3KtYhVgGOcZHBq20qqAHTB44/z+NDAFm3kjB/gFQsp5ADEE8jHYe9MTSY8/M2AAcDqPyqPCMrfMuGPAXqDQqsUVeADnOOooAYPvZTnBDe9O+grBKwydgHy4POfp0qNt0hHGGI6cCp/LRQFPOOp5FM2LkEYPA5K4pXGU9pLgA5IOAD3pzwkIecjjqBUknB68N90+lQvJwVAJPb/P407jtcqT/KCMYBP61Scq5Yk53fyq5MeMEEN3JOc+1VCgxnH1HXH/ANbikXFaEUoz2+bHBHb2qnOzNkbuAOu3mppXGQpbg+nP41DKo2kHdntzz9aauDRkXDfOMDIH61m3khOTtyM8c4rWnzvwecjHy9MVlXQVgcdGz0GKZSsZyscgja2DwNuKkSdgCjk+hIbpSEkJkk59D1x61TnlOc9MdM/WtIsb1Zcnl3KSc5GeR0qvgPyB+n61HHKjgFc5P86sHC/3s9MfyrVO5D0M+6PVSAeMnnrWa7KrYJNamoEBjhfm+lZMisWOG/WqQ1sal7kAbcc54zXF64p3H5ip5PJ6V2F8ygDBI44PTFcbrn32TORnp2rVbnlROeUt9pVuAMc98f8A16tWoYSfNgDJJ4pIYwZyWGF4IwKtTAiZdoyMDODwBmnLU0uadkN2dwyVx7fhWpAcsWCnBHJrJtWIXHG3qM+taluMux7459qxaGWVAPAY4PQVKBkgru684HFMWPIHUKRzU6rgsOciobGTxcqOOc56e1ShSMAgZxTFYKOnJ6VYiO4Y9+e2aTGWFJWEsqb2HPXGauQoGYEr065qrAhJwMZzV6OMKqeuOcc0thXsW1OAcY6dSP0qeJlwhHB6bqhRVK5J4PTI6HNThAwLcYx0NS2JFhFXcSAOB19qtwfKoX5fXHt61nA/KQCckYGB7Vat84JPcetK5aRqxMAQQDgnGPSrSIHAxlR2/wAKo2+GGeD2GPWraDOdpOc4+92pAWB8pOzcCD26H61cVtqcge/fFZ8RZmywJBHQnrirsJ5O4YHPANDY0i1A2QM56Dk9qurgoQSSMZ571nojMdw64GOOtXIiQq4HUEn8P89Kls0sRSq3QHGDgZ4OaIlL5XGTjqDViV0YHjI7r6e9RBwvO3I7beooLWw0j5mCkEAcceg6VPb4LIXGT1IweBTwNykEnGMYzxiojujkJyCMfQn0+lAlqWXIxnJ785/nTUVjgL8oxgZI60iDeAQvBPX0+tTRgxoEA5LdCemfepHsNAwgGcdDt64//XTAGEmcjHbByCfb9KcW6bNoz0I4zikiwqjaMKOmTRYewvQ9cc9+lSccj+E9s1EwJYPIcdCD7f5zSrlTuZuh28n/ADzQKw8qqACQAnnr2HtUchGwkDYvTd1/Ko2Vtx2Y2jgA9aZcb9rfw45BB60IfLYFKlgM5RRxz0NJvCE4I3dRk5FQCNt2AwGTjgdqewAYA9T07j8aRVhzMG6AdMYBqMKCCeACc9O9MY8HB49acZM8hj0x2OKAsV3j44Udfp+VVJUCg7W5B6nqatTMDg4Ye9VmLMME4I7etMpGZKgErE4xu5I7VC7BlICqD1zjirV0AWAUjOfyrNkLYYYyAOaaZTVyhcgANweOv51nzFduCQcg4x3rUmHzEkAn15xisa9LJGSOWyO+MU0O19DPnm2vkZ24GARWZdzBztXP1FXJHL7h3PXtWXcghjj7uelWirWJEnCHAyPXHrVqG9DuF5PpkdKyXOOh6880+A5YHIParRLiupeupF24xnNZxbnjn61fufmXgHHH/wCus2Y4fGT+BrVGeljQvW3Z2kMuOlcnrIG4ct0+bv3rprk5yVI56n+tcpqe2R354B29cZrVHlxRQhGyQ9MA46VJPICxaNiVJ+UetRRkLDI2CSBnJqOJ9yhSRtJ4NEjRLW5sWpDMFIOR2PrWradV+Y57isS33B2bcATxx2Fa9ooGMZOBjIHasmU0aibtoI4+tW7dR5Yz3/SqyHAXgcdDVjAVVySQfTpUMkeQM4XBwefapEBLD9cU3aq4BzknvUg/dnHBJ5pFIvWwC4Xjb0IPWr3mLsAOBg9jWSrnbxx6kVZSXcMDnvg+tJhy31NSJt6EAHnpzVhAXIAOSQM81itO6KAgOMdPT1rXsWyAzZzxzn+dS0XyNK5cjibdgj2wOgq6sXy5Uc+metMj+c5+8PTPSrEbEjIO3IHSkTcdBlVwRjH6irEDZJOCfSo0UEL0GD25qZFyoHrkZPYUkUmWowpwAN3XIFXUUEbznPp/9es2AbACDj0rShY8DPHQj2pNoaVi5EQG+b5R2JHSp9wfqzcd+hqqCCO/Gc5qzanLrhgQVxz06VJoiJgXBxkMBn6UhOGJzkEDqatSJ8wI5Az/APqpscQVum0cgDHSgpMaHAA2rnjkAYwfpQT8xIGVznj0zV4QDaMqx9TVaSPyyNrFh90Y64/pSuONgibbnOSeuamdwUIwcKewxVbBBwpbH8qf5WQCDnsPekVyjGkLAL6kcD+VOV2Lbu69venCAhvduOfQVN5AGAqjO0jnjmi4XRCZHQHdkZ61FK2UAJIxn73rT2iwwJJ9iRwc1CVZOOi46e1FxpISF2Oc/P8A4VNLNuUgnGTjB71UXaxU4XcOQPapQp4PHByCvai9huKuRPIckAEknnnvSRvvIOdxB/h7inSDLHABIGevPNRYKncu7Geg7VJdkSuqkHjLZ6/yqGZMEYBJKjiniQgEMd3J68A0rZc/N8zE4yelO4rFNoySFznHTPP60yaM7SvYdOOlSyLs5CgqTgA1BvLKQAMexp3BpmbKrZOSCM5z0zUTxAjPGW64POMVeucnGQSy9AO3viqjqwQqMnHOQe1O4My7kqiZJG05rFu8SgYzg1sX2STnjjgDqKypgW3EnOcHp09KaGu5hygjccbfUZrNuuQMjPp61s30Wfn6nvz1/Csi5j5/Qc9qtFJ31M50A4Ze+Kcq4fHbFOLnOPU1ZiQEAg5J547VpFXJk7DiMxqx69M1RkyWymcd8E1cmY5wAPwquRye1aozvYlvCNhXnOOlcrex/vgT0Hv+VdBdNuA4IyPvVgXA+YEliM5JrVHmRKE8e2CQNzg4yOcc96gtUDkDBZcHv+ua0J0G5hnO5eKr29t5LAMSQT6ZyKTNIluwQ5AOQN3ODW7ajcBkE5PTFZdqCGOeM8EY7dOla8a7SuORWchtlxThgByq1YXPUkZx2quB8mSF45x7VJCSRk9yPwqGIsoRkk8cYHpUxIBBAxgZyOhqvEcnk8dQSKtrhuM8fpSAjtgH6njn8PercUYd8AjJxnPSmRIFXZyQePpVhECkEMME/gKTZdy3FCmF4x6VoW6Db8uAOnTrzVCHqCCDnke1W4mwAGz179KloDSjk8tSCvHcHvVmM7sE5KnBOO1ZofOeW2jqauQN8uAcHHJ9KQWLIZ+Mg4XkL7Vbgzxgn6+v1qBPnC9i2M57irluCCuTn0PpSuPoWrWElR8wHox4rQjUqeApz2wR/n/69V4eV2N82R0NWQ5IBbJP1/pUsE2WPJHODjHBz39qbF8rkcgHkE9RSJLnKk/d5wP/AK9TxKGK7iysf09jUmidkSxxlsHcq4IGVHNP246YABwdw/l70KG52YAzn3Hv7UKxOWGeR1PUUDTuPRiQfvZPA74+tMcFn4JBHGCOtPVAoAOSSM9elAU85HzdxUlIidE3vg7sjgjginjKxlgAR16ZoO4Z2rgjnj2qNsAEDCnr8opFpFqNkyuG9sDufrVn5QoDMSO/HU98GshNxOcEDqBnrU5maMY6nHXHA96YpQ1HTEEBhjI4HGKpsof7nGemRyPeo5pvN4DZ5696lh27Rkli2cEHtSbNFFxQzaVILdWODkdPxqaVd3y5YsBt6Z/M1ExJ6lSTTDvzklST2FMfKP8ALCxMBkgdB3xmmhRlueQOntTt8hQZ/hPBHftimxI28s6jGBmkP1GBcElsLnn6+mPWo8FTtIJ5zyO9XGi/d/cJ5z+NQsrDAYH2zz+FAEbwBkG7nHI9qqSxCP5lxg98f0rRhHLEgEE8EVWvBuXvu5APqfpR0FfWxmiMtkkc9cA85qrchlb7v3e4q0XYbs/MO49/eoJ2yCQfwI607g0Y12AQRnAPByOPx9qxrwDdg54GSRXQXCgLz97qBWXewBEfnJHUCqTuO6RiXXIY4GemCefwrDuAGzkHOODiugnG3cuOvcVlXsYAbI+vvWi0BaGC/wArgkcHjmnxM27gkj2PWluhg4Y4GecDvTY9xI7AVpEJEpbc2fpz/QVXlkw3IYn/AGRUr7to4GOxqJsg84J9Sa1MmVnfKbR1dcVk3LZYEFQu7BOOtXZnAhXBOGHI61TZQQCfvYJH5VqechhGQAcfKD/n+VLMRmFei4y3HWpHCbFGQDjjOaWcMWTZztFKWxS3JoVBwWwPTitOAZwepxjGcYrMg3cAN0GMEY5rQjIBX5QQMVkxlhpBgL6fXpVmPgYIAbHbvVVQC5U8Z7VcjIDAZB9SKkeyJEYAYPH1zxUyOB0PzdOtQodqqc/j6VLEcuQ2CCc+9IpItxzAjJJyTjniribHA469cf41mxrzz0HqKuRyKD8/PQgD+YpBbsXoM9AeBVuM4BO7AGeg/KqcZHAAwPWrUZK+w9vSpYFmE57gjHXFXoQSDt69Kzky0nHyknt9O1aMTbVB38471JfQu2qnHXC56emKu7gq4HfnrVOJ8/cYEHJOOlWEYEgtgY5II70WJNG3kLKMNt7c9avxlGGfTvn+VZEW4NgdT0GeM1fgzj1OalodrFyDaEIZeO4HUVIGAcYBOcA+/wCdVVYhWPO4dMHnPrT4lJfBLccmlcpK5o253bTxgdzVk4Ut/EcEAdTVaEFCQOOPTp70uSz5AXOcc/zpMaRZYjy/ulkwTyf1oZAwfao6Z69BURbbld3KjIx2pUkO4qDyPTj86mxaGtHs3ZZgSenYc9KrSybZQTnB4HfI96vBHfjqvp2BqvLajALDqPkHWkaxaIEfAAzz37VHcPt+RQRu6jHB+lCIWOAEyRjryfrUskYYryGOMH/PrQy9NynEjMd+7JY89+lW0wgJO3KjGfaiEYUA5+UcAUGNS3yqCMZINMTldkfzCPaDx97kEimowPHAB+8QMfhxVsqGj+YHcB6Y49KglUJhuRkAfKO1Kw+boTiAEZCnPUnNNaMIfkI29GJPXNMgkbHfPAGTzin3MiyYC5wwx19O2KYtbkQnyMfMDnrzinDAO5CQ2Dnnr7VCiDbySSBnPXNSQpliMM2TtIPr1z7UrBKwhLGQ4GMHjA5HvUE5ycn7vOfQ/wCTV1wqgZcnH+1zjms65IkG3JA6cf56U9iVqzNniUk5zgtktjv61VLjbwDnpk9CavTDIx13dc+vvVGSDg5Lc/madir9ylIARk8A9hVC9TCsOCcY6ckVduThjk454wKpTuSCN2WzkZPNUkSzCuQT9w54AzjFZkyMwI71uTgO2CGI7kHgVm3SghgqgYPIPGKpFp9Dn5kJYjoMc1XAKsK0LlMOwI68GqMhy2c9PbrWqB6hKcEj17E5zURLE5BI/wA/SppUZUPIP0qk3Xjn61sjFoxIpGmXAYnGMjqKnjgThmBLls45HH0qhp2VtkVRgBefb61pQkkE8EEZJ64z61o9DhHCIG442kZ/IenNW44wQysF9QRxioo4maRs8nHHvViBSXcjK8Y470mSVrdCrNzkZyDVxGGcAkr65qtHGyvlwRg44qwFGOMbs5x3rJmiVyxCN5XABbowqd+MYIzn/IqvEccA59DU6fM2STg80h7D4Dn73qOOlXVYeWrKM4HbvVJcsRjn0qaMlWIGOP0qR7lqE/MdxGMcZNWxyRkg81UQg5C45HI6Vbh2snU4YcHGcfhSYFiLqDgBTyM81biyW29CegzUKqR0UFscZ7/4VOvKgqcd8/41I0y5CwEm3sR+NXI3DgfMeTxxVFIwY8g4J6HjPHep4gTkMxGePb6UitHqXowOzZGPT/P5VoRuXI4Oe+e2KowSLhsjvjOcDNTxyZc4YYwTg9qdhdTYt1LrhsnpjPerkaZGQAT3NZ9tPuAJYjAzj0/GraTA45BAPPYdKhisywqMCv3WGcdMk1oWKJuBI4Y/MehFUVclW8vb5gX5A5wue2f8asxybR87fvFxkp0zjkDNT1uX5GzdRRmIMvU8ZBz3quu0AqxyPug/0pIp9yKBwucYHf8AGmSBVb5cYGTk9/cj8qHZjXYk2/NtGOAAMdvxqeBYmddnK9Dkck/jVHezDA4VhkgdR681ZhfG0ZBx3Hb6D+tQy2i9tRAcAd+T1qm26SQhWy2eB35qVJP3TBSrHrgkk4x3pIsg7jj1LdB+dIF3KzRbV6AkcH/PeoZAxQHocc9uKvSSKDgqMYwAvUetVA+5W2BivqePwoNFcrxoqk8/Ljrn8qn2rjBGABnGOn1qBmbhgcc5GRk49P50x5iQRtO0cnnGeaBtXJHnCrnBKr19PY1HvWQ8qAAO/vSsu4KRuB5JxUTJt2kHJb+H2phyotRxgAhMZwCccY9qJEXA3sS2CPSnW/yqSVAGRnAxn6mmXBO1toyRxj39DQGtyt90hA3OM9e1Lvxzz7EDJNNkdkGTGRxx3GaaZSdwVTuHt0oGFxNuAJGQDwKpO2ZcAhsHGKndSoxn8v51XkQAcnkeh9qBpJCMoZPm69MHj8ao3gyrYGSeQc81YbJzgcjnjmoHTJ+YKB2z6VSItZmNJuJ+XKk5xxwR6cVScF+TyMY5/hrVmicpiQrnjO0Z4qpPCGXG7OcLxTWpaZkSRgEjDAKc9KqTjkFT05x1BNaNwCoYFTkdFPU81RlJLg4wTyOx+hFWhtMxrqLaDwQ3Xp1rLmTkkgZ9h1rpJU3I67RkjP059ay7i1O9soBjpmri7iT7mdkmJ+F4GPfNZspKOQe/PWtYx7A2OV4xjnFVGQbjuHNbRIkuxyenZNtF0BXjjp071pxDbGCSDkdM9ayNGDi3woG0jABGM10EKggqAMrhc9etbM4NhYBwNo9M561PDy4I5H0/SiKMmdgcsQAAT0q9FHhWUAbehwagTaIntSMgqCT3/pUIUEA4O4dc1rsCIlA9M+9VWjKzcD5SOtQ0OMiIqABknPfFKrg5Hp6VG24Ns6belKo2568jnNQyrE8bbVLc9OhHFTRYwQRknOaqKxwen9BU6S/KFyeBgZ6UgLETKxwoOR1Bq9AwDDbnvjHFUbbaw3HkHtmrixhQT+ANFh3NGNwWUKcd8Cp1IyB296pRcJkYCnr7e1XYE3Y5HPI9qkCzE2CSMHHGe1WolypHJz3zVJGC4U5J/lV+LoAQBjpx3pJDvYtwoqKBnJ6Y64qwi4QMhXOPl9xUMYL5Y55559atxY68AHqM9aQrktsCuMgfQ85q1CvmMBkjByaYm1t2DuqSMFWIYc+gP+eKllpl8AhV5HTt6f5zU8OCw6gAdCPWq4cBM5IUHB96I22MNpJAPyj+9UtXKRrWrhHwW+U8A/Sr0Z3x46ZyMHgDBrNjG5M5wB0HXNPjcqybwTnOexNLbcaRd8obj0JBxt9akYKUZ1Xg9ecYqqs/ygEHA5yDn8/enAk8jbyAeaRdmPjRlkwcN7mpkdVUBjhTkYAOMcVA8ykqQMjuevHao2lwrKoOenFSOxO7ZdgCSOMd/wAc1CYiSQSD6+lSQlcYAI4+YE8mkaRd37tdnHBU5BFAK5XmBXcBkYHX1+lM2CTGGODznrmrUqrIUYnnp071D5bL945A4256E0jSI5Iwductgd+1KyjaDgA4qGJuGHOQT7GkHzDD5ORuC55H1oQWJSVRUHUEc85qN3B7MCOcepqKQMcM2CMAHjj6UMu0YwysAOmTgen/ANejYqw19rqvyjB7k96aV2knOeoAUUxhywC4Hr6fQVYXJRVwTxgnGCc96YnoU3/1rFQcKBjBqCY/KwAweOnBz71dkTeM4LJ656VVddxbg59v880BdFBzkgdByDgd/SkcY29znv0IpWOMHnn09O4xR5gILZ/AVVxuJVcr1PDHp6/j61WuWbGMEZ49/wD61XpYt4yGIHAB9MVnyOwVQzcZODmhCsZtyp5TaAOuc8n3rJuBGXLLkgjr/hWzeZkTbnap9Djj/PasqdNjEx8Ad8e/SrRaKBwZMjLAH34/xqaZflbaFBxwD0z7044KgYCOc9OcfWpC2YzuXacferSBnMwbyIocdyuSKzJozuG1hjFbN9Hn5SMhPb9azHIDEFSx9QwFbolvQ4fSMCKMgZKrnb6it+yG5Sx3Y6nA4rC0hgFi5w+wDnjJro7KMBQOANuR6fjW0jgZPCAj7gQCRnnoPpVqAdN7DGevv71AAOVA4HIzVqMHcpfsMAdqgksD5/mOQB0AFRbcE7wdw7Y6VYgIXqeOme9IFJl2knjJJJ/rSEtCpcWpHzL+FVSuJCh6kc1soGI5wcdMcCsy5+SY7zySfzqJIuLb0K5BUAAcg9qlgzyD29cc0wgAqQO/GaljjLFiQSCPXAqDQliJVjnkg4NWUlyw3dOO38qgCkjIBxnoauW4AUNzwenoaBXL0KsyfLjjgCrMBKqRnJ459aq25G48Y57jqKuQ/N9314HT61NiblhUJYfN7ZP86uRgLGACcg8nGc1FHnaR1GOxxge1TZC8DIYde9HmK5ajJwN3K81fgBweg6sfSsdJjjbxuOM5q9HIQPlxgetItJmlGQihlzkHvx1pY5CZOAQOgAFVopCVVuAT07/nUqyBD8oAHXFBcTRi3YbPJXsD1/zzUgBR9oBx247YqrE525P3jx16VOjF8cFWJOQT1qWWjTt5ht2yDqc5PUGrgjV8b84weDWRBvQ4A4X07DsK0rdyQuWH064FZsduqJRFtLGMHaB2HSo5JGUFQD6D1qRpGBOVCsDxhs7lPQ+1Rqqz8pktzx0/yaVjSL7jd7kgkAMD69R6VKvDFlAODyccCpYYTg7D0PGMjn8astbhVzn3OaQ29SBMbQcbQemB3prgn72Cc4yetWSuzOMZznrnPvVedd6kqAPQr0FIEgDCTPUAdeetMXzH3naCT2H5DP8AjSxI+CzkEDnIqxGhcAELnJGc5oZpsVTFuYbMDjANT+QdnX73QZ5OBVjYoGSuM/MevPX/AOvVhXLR8MpCgYHT/wDVSvYlyMaZcM2CMHnpyCf50i7HJJ528nPUip7mJmPQnnjHc+3tUQiKjkAbTyMfyoK6EcyLgEYU55Jzz2xUIIQgE529yauvDIdp+Vhx1HNMe2wu8bsDqR+lAitLIhVhkEjoAO9ZsswG0A/MeMk96vXELHduXr97IrIv4G2fIfl7c9cUrlxiRSMsinYQCDyc80mFiBIwSOig8ioYY5PMyoJPc+lWL6NwhCBCG+8elNMt22GPOEUsc46+1Vo4xcSjG19pztbgHvj6VO9p5kzKpLgHAx6+nP0qxp1q6Y3AseucZ/DNXG7ZDSSuZ11prBUBAG3AC1n3FiTCSDn+ldVd5A7kgY6cnFUdoJfOMdRj+tapIy5nY5T7MQC7Pnnn0pjpuJXupx+Fb15EOTgf4ViXZCSMCuB6CtFoK/MZeo2wjUnjByeOTisCaIGQ5Y/lXQXjZBIJ5/WsWWMlyQfzOK0VuordzgNG5SEZOGA5POK6iBicdQc4+X0rk/DciBLZ1z0wAfXHNdTG5SJeoYnjNbS3PPZcUMXUqT0HI57mrSngkHOOmTnNVrVlyATyCPbFXY4vlIDDJ7+n0qRBGcsAc/jxk1aCDAx82OmB0qGIApsJ+fOORVlfu4JwSO/ekDImI3KcZ9QD3qG5tlmPmdSvGParLj51xjIHHenLkbkbnPei19Bx01RjyR5A+UgdOKljDBecDjoa1/syyqQOuTzVWSxeMg4znngdKhxsVzX3KqDJ68dPxq1brmReRweo6VXeM5Hytye/GatwfKQG79OMZPapG9i6BgNyAOnSpIxtIG44HtUcQ3EkscZ5wKnEZLD5unOaTRK7FqNjjJORjk46VbiAdAGJGOPaqUER4LADuB1zxVhMBsnHIwRnPNA+uhMYl25UY9KISQGK54PenbjxggEj06UisFI3BeQee1SXEtxyEBODn/a5zUyNvJUHJ7gcZFUVkUE544GfXP1q2PvgnlTwB6CpZaL6Px8pPTkhuTircUuxTnqRkDGaoxSgEhuR1GRzVyEkzFGQY2jD55J75HtSZaZdhmw2CMdgRVqN8scHJX1GDWekYHC84A+nX1/rV2JfMOOeOw6nis2ytC0kpbKkgcdSPvGrMLDKjcOOMdPxqmkW7AxweRnjFaNlYtLKjbCqk4z0P/6qVrmmhdgwzArglhkDGTn1q0tq8kLnbhc9QOn+f61e06yCovmFScZGOCRW1HDGjAKOR0HrWsaTkYTqKJza6XIWzjHT+HAP0qV9HKRh1CnttJPA9veul2gj1FNl/wBWwIyDx0zWv1dJEfWJNnKvYlSBjlBnGP0zTItOdODlTk5Of6V08aZYl8Ag5wD0/wA81MY0xyoOBjmo+r36lPEW0OTltn2nfnco5OP896tWlmSjHB5HJ4zWzPbq0hODhj61LFEEGNoLAY/D/wDXUrD3dhyrqxhT2GG27X5HUj3qpPp7YYIM7ec9QD/hXVmNCoHBA4GefwqLCdOPUnrTeGt1JjX8jnf7LbB3A5xyOgp403ZGMADnkEHr+NdBGq7mXHqff8KinA3bgTnknHb3odBJXK9s27HJX+mFmbYOd2evQ1VfSg7NujyQeewz7V1Uygk/ICcfe6/WmtGjKAFQk8DJPX/IrLkRv7R2OQj01d/3QQTuXjrVa702RD904B54zmu0WFIY1IwCMLgLVO6I5C4PfIxk+o+ntRyIXtG3dHLR2oRcEZwDn5aa4ESnG3bkZ9vxrUvNoJCoDngZ/UisqQltwJ3YB+bpx6fWtErFJ33KN2VcYB+bGfpVFyGUjIZeTyea0J49yHO4j2HSstSd7bju47Dv2qkOxSkLMxdvvHo69B9ayrsLu+YZUd63ZVd243Ek4z0/Ssq7jKscYGO3bNWiephXCEb1UZGCSB1P0rFmUGQ4H5itu7AIP94dxxVCUF23Dn/gNWtBM8c8NSbrUJleM4HFdpAxKjIxnnjn8q888NzbMgjJUnHH+fevQbBlcKQOcAZB/T9a3mcLNKHiZmPfAHsasQuSflBz09jUMHGSOSODnv71ZjYh8MCTjr2xWZNy7bkbucEA9cd/SpZgcgdSP1/Gq6KdmNmD1wTnAppmBVQSR/tCgVrstHCLyTnHpSBCWBJwMZNRhl7E9s9smplO9yHOS3Qe9Ulcdi3D9xAMYHGatool+VuOpz61RDsqoQckHmtC3IPXIz265p20MpIa1mjJwPm/r9ahlsW35Aye3rWkrEAEdu+alwMcnHHNLkTBSaM6O0ZUOV5AwB61ow2iFCCMP1PbFSRTIAVPrj14pUkOQEbGB0xn/PajkSHqxsloS22PAHt0qs0Eox8uAPXvWnZuS4Vl+XkZx0q0yLtJCgjoOKXIi4uzMjyJliGflGKYUdXzgjjnv+VbojLxkcEqMgZ7+9TR2se0KVBZsnI9Khw7GinY53acbQMr9KsxjCYOeecg4z+FaU1g0anYCTnj61AtnKBlcbvccYNYyi0axkrDbXad3HTow9Kuxz4YtzgdcdKhitmLI2Hx6jpVtLR2TGCT3+lS0XdXLFtOTwDy354rasEV1ZQ4YoxRlByVPofQ+oPNYQsZ5YbiG1uTbTyIVScR7zGT/GB6jnHocGut0HSLXTrCK1solSBeinue7E9yTkk9yaOQJWRbs7Fdw3ckdAOf8+tbsUSIuBnvkA9TVW3XaCBgL3x2FXV4k65A5wR3/wA9qfLYnmLIiMcQxhW5GAccU6FyBu5YYzknH4UsUibTuZQAMkY4qZcHcvfvitYx7GTfcI2wvUYUdz0Hc0+UlQWXkgdKcox0xx6VDeMFgYucL39a12RmtZDIZlyqklT3471LK7AZVSTz9azbd2VyzHK9ABzVxpQFH3gBxnP8s1nGV0azhZkkbDec8c4BI6055SmSFyBwapC5cvgfN3+U9KDICqhSTjjDUc4ezd9Sd3EjEFNwzxg5OfpUJfq5w2cjJHBqGGTMhMWAAOpGCfwqlqN2VIJGSo646nHaob6m0KTb5UbEcihAvceo6nvSTSrICpbkjpjOR7Vl2twHTkjeRjGMZPuP89KQu4m3EKBn16Hr0qXPSwexsyw2CS/ZfmH9KVSoB2gnAzwMZOKrtIQMnleo9c1XNxv/AImKqO3TNZmnI2XJpFZSoAIz8uBgn2rJuDh8ZO8cZHv/ACq00mFzKMAAVVZsyMAoUfXoT3ot1BRKlyAyjaF68A8j6D/Pesu5UI7AK2GPHYcDpV5ZjJG7PE0QLMNr9TtON3HY9RVS5ikY5yPm71S8i0u5mTMwGSucgHJ5ArInOJQTlSOckda1rlCoxhdox3rHmZkkIwAD/PPb2q0WkhrEqWy3uOMmszUJN0hUhgo69+K0Lh964JLMvP4VmTgjcG7HmrsRbqzHugVz156A8YrPdWYggsuRyK1rhccnkd81UfYpAOBgcVSRMmfO2iHF66dOc9OAPevQ9KcNCVYYkwO+MV5vZP5Oq8KCN5GDXf6WQNjnKrwDj3//AFVvJHCzo4WICKSWHcAVcxg5U4Qj1rJtWzKy5IBT5fbHr79K0LaTMcR5IMfI6c+tZkWL8IUqhHyk/eOeuKc8YL5QHIquknKBu5AJqeSYqp2YBBxx/Oiw0ncvRRoIxK4OAOtJJCoKzFmzjv059B61CJeHVMEHbxn+lWGBkVI1OW7/AEq1oCTRJ5i7CUwSOSPX6VLDKzpgZPduMZ/DtUMUfl742I+bpV23iKsoXgN1+lAmkiVJTtZpCR+lOiLFVy2RjpmmMQfMjbqDkc/lUjwPJbtsfy2KkBgAdp/+tQlqILclpW9SeFLd61bOIGM4HJ5PPb+dZVrCRKIy5kfb8zEYJPr7c1p2JKnY6jgZ55IoCfkMVtk7BcBuuPStGFt0eSB65PastpVN2QxyAT2rSBDAbCMf3qFqJ6FlDmRsHvn6e1Xrf5W2sDnHPrWekeTnkgkDGOR71ownLAEAk8YxyaVguSSBSpDYI6gLRGE2heAvr71DcyYRj7/e9Kigcsew5x14qWjWC0NG1t1d8qAOeeK0vsiLFhgAe3H6VSspthUkL6gEYz/n+lXnm3QuVUADBwOlQ4j1uUYcifBwMHJx610dp8wALZwO3GB6VyUbyC4wAzc9W6fSuqsiTGrZK8YAqLG9SNrGxFKUXCneB37fjVlJS4UKFIGCAazbYbjnGWGM+h/PvV1ZFWMgdAOvXn+tKxFiaQkYChc5ySeav28i9AQcYyy9Ky0kyc4Ab7pYetaFqi4BwPQe1VF6hUXu6lsDnPFZ2sTGOHggHOOR1zWgD1BHI6A1h+IXHToBwRxz+NXN+6Th481RIm0wrIWJPHDDcOp9z/hVi6XaccHvgDGP/rVV0P8A1eWB9Du7Gr10Tu2glQeSW6VCj7ppU0q2IEgzgbskccDgUkoAXGAy9j0x/WpkjKxnDlwepLc49PpVebJTnlOeB3OalqwJ3Y6IbicEgngk/wCfSqGqwJtwT0HBHABrStkIYEuFYqOe+PaqupICwViMHBGOmf8A9VDXumlOVqmhS06MBFVWzjjnrgfzOKvtEAu5cKc5II61PZ2wEIxgLnoBkH1NOl3qWAXcAABg4+lSoWWop1eaWhl3o2KVVgFPQ8c1mKNx2HqM4+ldHcRB7d2HOMEexrHSERybFw2evtUtNM2pSUospOGWX1DL82eR+dI0ZwWIIIGADxmp9ShYRMnAbdwSML1B/pSiVWGVUMX9Ox+tFjTpcq+UQWDEfN154qnPlEby2bI4IwOefetCbJAVSFA5OOpHX+VZ9wwwVBz3Ixj8KpKxDVzMuEGQWZsjJPHU1kXKgkgjJxz2x7e1a11KRk7ieOSenXrWZNB8hOOScA1aLS7lCZR94YORjI9aoXKgvjqTxk5NaDjMRXtyflPIrMuXbzJ8qEWNgqsDnfxycdsVaRLWpBcwYhBV8gDBOOtZMuY5CpB/AVtlGZD0LYz7VkTRgSMNrH6dKuKMN3qfM0nyagxUn72c+1d1pJLWfUA4JGeBxzj8q4jURiZHGMEfnXW+HZc24Q4OAVwe49q3ktDkZ1NqzB43BUFvfjB//VWhAv8AoqsD8y8ZP1rOtE2wLgBSvTjpg1pRSZ83k4xuyB1JHb9KxsTctqE2RnIDh+T2xU7xDZIM9T+dVw6/Y2YgHGM49RV23AaLcQPu5AB/WjcE7Ia3E218gEjj2/rWoFj88MMb/QCufnmc3gzwQQQPStsBm2MoyvBPPT1q0XOOxblQyPjbgHGTUiKsYG4biONq9arrKvnKCcg8HNWS5WYmHk4xmmZWHW5DXDh1OWUEA+lXYHUQMoG7HYVQj3yXisxYZ4JxWgkRViFACnpj1pWsEhEP74Mp+UnuKsp8s7EjGTgY96bCoaMoDkdT3pJF2Sp1PcYHWnuQQvGy6iDyEY5Bz2rUjG0IVznH4iqlyxEg2gA+np+FW0DkoWAI7D1pbFSd0i1ak4JOA23mrTSbQCAQG6+lUQ6qDjGCTznr/nipVkTKjByByOv5UmCXUklV5A21QD056VNaDC7SvOQRkdKahU4AOT3/APrVNbvHuY8ZPXjr6UmapuxajBZlC5AHbP61aO9IGypI4yTwcmobJvTr0G41buTmByrsRjGeuBSKW6RlQOfteB3PP0966yxDeQCRzjAHtXFW85F7k9N2c5xmu408jyEYA8njsai2h0101Y1IYlZWO8ZAGc/4VFcIy/d3MvoBjn/9dJFdbfTjPfP0GPWkjnMmercZJ9PzqbGcE7lyzTKgk4Hv1FbManZk4z7VhI5jfGNwJ7Hr/jWzZPutxxyDyKcNWTXi7XLAGO5rm/EeC4VsgbuoNdJmuW11vNvBGufvcjPWqqLSxWCV6ly7o2/7Lz0IyeauMCsg5OP5f5/rTdLQrbqcHBGT70yQkvhck5xU2shzfNUZeDDZucFeMA96huYw2QgO7sR1qeJFVD8nXnHWkkUAE4HPGM1TWhzp2ehEu0A4HBHAx09qzbkr52DjAGc9q0gu0MQSCODk/wBay5y0k64OQTgYFRI6KO7ZqRyLHCvDZPOB/WoJZ1/usMA8Dn8h60i58jy/mPJyCMVCQwOcHkDn2psUYK92TSODGVbBBHfjj0qvCyHD4II6c5AqSQZiYAnJGcDvUCg7skEcbeOjfX9aho0ilYqaioyT1bO449Kq+WQh3YAXOf8AZrQvI3ZDkHjleOKzZcxIckntyOv/ANelynTDWNiRlLg7AW4yMnj0I+prL1ABRzyfUHpWnatlNm3uAR/nr0qprXnYDQpG5LqGDttITvg+vTjvTQkrSscrdszsMhcnrxyPfFOZmEG0uMkjOatvF5lycAZ7/LQ0BUAAHOfTv600bVNkjIdCFJ2jPcDpmsu+J81snAX05z61vNAAGYY5wfcn61j3UQ3HPbg98VZjbUoXHyRhScf0PWs5o0lYuQmSe5rWnixkHHPYn9Kz3gwxBz+WatIxaPl/Uhm3iIAB4zWp4clYl8YztBIPQ9vwoorolscR3NnIHzgE7gGAboOKvRE+dA+T8yZx0/Ciisehmi5A2XKgDa2OvpVuHKxoOpx3ooppajFuYcXKhtpJAPtWwm4264PzdPyooqipvYrzsfNRiF5Hy4+mau2iGQlS2MjI46UUU7BLRGhsKouTkDmpHcoSDyQRz60UUMzRNCWUMAcZzSSlgQC2QSDRRRa4CXZAcMRz3+lXIJD5e1WIwAf6/wBaKKFqD2Q6VSoznj2ptowdQCOMkH3ooqbFrY1RHiMMSeQDwe1Osiu59o4HGMf596KKXVFR2NW32iTkZY984yKsXcgS2JXIGAcUUVLLj8SMewjMt6GJ6/oM11KM0MAzjHJyvXpRRSR1VfiSI4rgmQgDB68cVp2gLTqCADjnk84oorNjJSWLCSPCqvbkYrcs5D5aICfYn0oooW4q691Es7HyN4JCngD0rFtbb7VdyOSAQwH1oooerRFFuMJNHRRRCOPaPxqvPGPNUKoBJFFFaM5IN8xOuBGx7envTHky/HHOKKKT2BbkVyzfZ2ORgD054rMtDumZjnGQODiiioludVH4GbBAcYbOCOvf0qMxqQCc4wBnPPrRRVnMm0QXPEajjjnI61DbY24YckZGOwooqOp0L4CC6G5WYcjdjBJrOuBkAA+3I6UUVJ10dkNiBVlYYBbtjjj/APVVa8OdwwDjPJ7Giikt7FrWRkNIE5Cgnr07028mQxZO/HQfX/CiiqRclszNuHYIy8Bi3GBwPWsmc7mckAf/AFqKKtbE2M+4yRknOD1+tMJKhTnORnmiitIpPcxqI//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large caf&eacute;-au-lait macule on the flank of a young child with neurofibromatosis type 1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the Yale Dermatology Residents' Slide Collection.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_4993=[""].join("\n");
var outline_f4_56_4993=null;
var title_f4_56_4994="Patient information: Groin strain (The Basics)";
var content_f4_56_4994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/39/20083\">",
"         Patient information: Exercise (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/21/36179\">",
"         Patient information: Giving your child over-the-counter medicines (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/0/39938\">",
"         Patient information: Muscle strain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Groin strain (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/groin-strain-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1145738985\">",
"      <span class=\"h1\">",
"       What is a groin strain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A groin strain happens when 1 of the muscles in the inner thigh gets stretched too much or too quickly, or works too hard. This sometimes makes the muscle tear. Another term for a groin strain is a &ldquo;pulled groin.&rdquo;",
"     </p>",
"     <p>",
"      A groin strain can happen while exercising, such as from suddenly changing direction, or during an accident. The muscles involved in a groin strain are called the adductor muscles. The adductor muscles connect the pelvis to the thigh bone, and pull the legs toward each other.",
"     </p>",
"     <p>",
"      A groin strain is the most common cause of groin pain, especially in active adults. It can be mild or severe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1145739000\">",
"      <span class=\"h1\">",
"       What are the symptoms of a groin strain?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some people feel a pull in their groin when the strain happens. Other symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Muscle spasm or tightness",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Bruising",
"       </li>",
"       <li>",
"        Leg weakness, or having trouble walking or moving the legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1145739015\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. Your doctor or nurse should be able to tell if you have a groin strain by learning about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      But some people do need tests. Depending on your symptoms, your doctor or nurse might order an imaging test such as an ultrasound or MRI scan. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1145739030\">",
"      <span class=\"h1\">",
"       How is a groin strain treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A groin strain usually gets better on its own, but it can take weeks to heal completely.",
"     </p>",
"     <p>",
"      To help with your symptoms, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Rest your groin muscles and avoid movements or activities that cause pain",
"       </li>",
"       <li>",
"        Ice the area &ndash; You can put a cold gel pack, bag of ice, or bag of frozen vegetables on the painful area every 1 to 2 hours, for 15 minutes each time. Put a thin towel between the ice (or other cold object) and your skin. Use the ice (or other cold object) for at least 6 hours after the injury. Some people find it helpful to ice up to 2 days after an injury.",
"       </li>",
"       <li>",
"        Wrap your upper thigh with an elastic bandage or other type of wrap, or wear compression shorts &ndash; These things can help support your muscles.",
"       </li>",
"       <li>",
"        Raise the muscle above the level of your heart (if possible) &ndash; For example, if you lie down, you can put a pillow under your groin or thigh. This is helpful only for the first few days after an injury.",
"       </li>",
"       <li>",
"        Take medicine to reduce the pain and swelling &ndash; If you have a lot of pain or a severe groin strain, your doctor will prescribe a strong pain medicine. If your strain is not severe, you can take an over-the-counter medicine such as",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?19/35/20021?source=see_link\">",
"         acetaminophen",
"        </a>",
"        (sample brand name: Tylenol&reg;),",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;), or",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      After your pain gets better, your doctor or nurse will recommend that you gently stretch and exercise your groin muscles. Stretches and exercises can help strengthen your muscles and keep them from getting too stiff.",
"     </p>",
"     <p>",
"      Your doctor or nurse will show you which stretches and exercises to do. Or he or she will have you work with a physical therapist (exercise expert).",
"     </p>",
"     <p>",
"      It&rsquo;s important to let your groin muscle heal before you play sports or do other activities that use the muscle again. If you don&rsquo;t let your muscle heal, you are likely to injure it again.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1145739045\">",
"      <span class=\"h1\">",
"       Can a groin strain be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can help prevent a groin strain by warming up your muscles before you exercise. You can do this by walking or doing another light activity. You can also prevent injuries by doing exercises to strengthen the muscles in your legs and in the center of your body, and make these muscles more flexible.",
"     </p>",
"     <p>",
"      If you are not sure how to do these things, a physical therapist or other exercise professional can help you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1145739060\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=see_link\">",
"       Patient information: Muscle strain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"       Patient information: Exercise (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=see_link\">",
"       Patient information: Giving your child over-the-counter medicines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?4/56/4994?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83725 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_4994=[""].join("\n");
var outline_f4_56_4994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1145738985\">",
"      What is a groin strain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1145739000\">",
"      What are the symptoms of a groin strain?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1145739015\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1145739030\">",
"      How is a groin strain treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1145739045\">",
"      Can a groin strain be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1145739060\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=related_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/21/36179?source=related_link\">",
"      Patient information: Giving your child over-the-counter medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/0/39938?source=related_link\">",
"      Patient information: Muscle strain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_56_4995="Econazole: Drug information";
var content_f4_56_4995=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Econazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/30/31203?source=see_link\">",
"    see \"Econazole: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/18/22818?source=see_link\">",
"    see \"Econazole: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F164104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antifungal Agent, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F164064\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea pedis:",
"     </b>",
"     Apply sufficient amount to cover affected areas once daily for 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tinea cruris, tinea corporis, tinea versicolor:",
"     </b>",
"     Apply sufficient amount to cover affected areas once daily for 2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cutaneous candidiasis:",
"     </b>",
"     Apply sufficient quantity twice daily (morning and evening) for 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F164083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/18/22818?source=see_link\">",
"      see \"Econazole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F164065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as nitrate: 1% (15 g, 30 g, 85 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Occasionally, longer treatment periods may be required. For external use only. Avoid contact with the eyes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F164048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), tinea versicolor, and cutaneous candidiasis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F164102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Dermatologic: Burning (3%), erythema (3%), itching (3%), stinging (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Pruritic rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F164051\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to econazole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F164039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Irritation: Discontinue if sensitivity or irritation occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For topical use only; avoid contact with eyes, mouth, nose, or other mucous membranes",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F164099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetotoxic and embryotoxic events were observed in animal reproduction studies following oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F164067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F164052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Econazole Nitrate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% (30 g): $30.93",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13457220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reassess diagnosis if no clinical improvement after 2 weeks.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F164054\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bismultin (GR);",
"     </li>",
"     <li>",
"      Derma-Coryl (AE, IQ, IR, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Dermazole (AU);",
"     </li>",
"     <li>",
"      Ecalin (HR, RU);",
"     </li>",
"     <li>",
"      Ecanol (IN);",
"     </li>",
"     <li>",
"      Ecoderm (ZA);",
"     </li>",
"     <li>",
"      Ecomi (HK);",
"     </li>",
"     <li>",
"      Econ (TH);",
"     </li>",
"     <li>",
"      Econaderm (BB, BM, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Ecostatin (GB, IE, NZ);",
"     </li>",
"     <li>",
"      Ecozol-VT (HK);",
"     </li>",
"     <li>",
"      Epi-Pevaryl (DE);",
"     </li>",
"     <li>",
"      Fungazol (PK);",
"     </li>",
"     <li>",
"      Gyno (EE);",
"     </li>",
"     <li>",
"      Gyno-Coryl (AE, IQ, IR, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Gyno-Pevaryl (HU, LU, PL);",
"     </li>",
"     <li>",
"      Italconazol (EC);",
"     </li>",
"     <li>",
"      Micolis (AR, CN, PE, PY, UY);",
"     </li>",
"     <li>",
"      Micos (IT);",
"     </li>",
"     <li>",
"      Micostyl (BR);",
"     </li>",
"     <li>",
"      Myleugyn LP (FR);",
"     </li>",
"     <li>",
"      Penicomb (GR);",
"     </li>",
"     <li>",
"      Pevaryl (AT, BE, BF, BG, BH, BJ, CH, CI, CY, CZ, DK, EG, ES, ET, FI, GH, GM, GN, HN, HU, IL, JO, KE, LR, LU, MA, ML, MR, MU, MW, MY, NE, NG, NL, NO, PH, PT, SC, SD, SE, SL, SN, TN, TR, TW, TZ, UG, VE, ZM, ZW);",
"     </li>",
"     <li>",
"      Pevaryl Lipogel (HU, MX, PL);",
"     </li>",
"     <li>",
"      Pevaryl P.v. (HU);",
"     </li>",
"     <li>",
"      Pevaryl P.V. (PL);",
"     </li>",
"     <li>",
"      Pevaryl Powder (PL);",
"     </li>",
"     <li>",
"      Pevaryl Spray Powder (PL);",
"     </li>",
"     <li>",
"      Pevazol (PL);",
"     </li>",
"     <li>",
"      Polycain (JP);",
"     </li>",
"     <li>",
"      Stazol (TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F164038\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alters fungal cell wall membrane permeability; may interfere with RNA and protein synthesis, and lipid metabolism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F164050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &lt;10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to more than 20 metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (&lt;1%); feces (&lt;1%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Heel RC, Brogden RN, Speight TM, et al, \"Econazole: A Review of Its Antifungal Activity and Therapeutic Efficacy,\"",
"      <i>",
"       Drugs",
"      </i>",
"      , 1978, 16(3):177-201.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9400 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-4E1BBEB838-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_4995=[""].join("\n");
var outline_f4_56_4995=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164104\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164064\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164083\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164065\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164035\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803129\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164048\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164102\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164051\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164039\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164099\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164043\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164044\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164053\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164067\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164052\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13457220\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164054\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164038\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164050\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/30/31203?source=related_link\">",
"      Econazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/18/22818?source=related_link\">",
"      Econazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_56_4996="Langerhans histiocytosis CT I";
var content_f4_56_4996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F58182%7EPULM%2F69891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F58182%7EPULM%2F69891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic changes in Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 204px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Langerhans cell histiocytosis (eosinophilic granuloma) in an adolescent boy characterized by multiple cysts in the upper and lower lobes. The cysts are interspersed throughout the parenchyma and have a slightly thick wall. A posterior right upper lobe nodule and confluent bibasilar patchy lower lobe opacities are also part of the disease process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cystic changes in Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Langerhans cell pulmonary histiocytosis (eosinophilic granuloma) in an adolescent boy characterized by multiple cysts in the upper and lower lobes. The cysts are interspersed throughout the parenchyma and have a slightly thick wall. A posterior right upper lobe nodule and confluent bibasilar patchy lower lobe opacities are also part of the disease process.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_4996=[""].join("\n");
var outline_f4_56_4996=null;
var title_f4_56_4997="Langerhans histiocytosis skin 2";
var content_f4_56_4997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F69504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F69504&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow-pink papules with scale are present in the diaper area of this infant with Langerhans cell histiocytosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_4997=[""].join("\n");
var outline_f4_56_4997=null;
var title_f4_56_4998="Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information";
var content_f4_56_4998=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/9/39060?source=see_link\">",
"    see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6215528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Kinrix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14790063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Adacel&reg;-Polio",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6215688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial);",
"     </li>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14790522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Booster immunization:",
"     </b>",
"     Adacel&reg;-Polio (Canadian availability): I.M.: 0.5 mL",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6215824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/9/39060?source=see_link\">",
"      see \"Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Immunization:",
"     </b>",
"     Kinrix&reg;: I.M.: Children 4-6 years: 0.5 mL;",
"     <b>",
"      Note:",
"     </b>",
"     For use as the fifth dose in the DTaP series and the 4th dose in the IPV series",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Booster immunization:",
"     </b>",
"     Adacel&reg;-Polio (Canadian availability): I.M.: Children &ge;4 years: Refer to adult dosing;",
"     <b>",
"      Note:",
"     </b>",
"     May also be used as alternative to fifth dose of DTaP-IPV in children 4-6 years.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796188\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6215828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Kinrix&reg;: Diphtheria toxoid 25 Lf, tetanus toxoid 10 Lf, acellular pertussis antigens [inactivated pertussis toxin 25 mcg, filamentous hemagglutinin 25 mcg, pertactin 8 mcg], type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate, polymyxin B, polysorbate 80; may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F14790523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adacel&reg;-Polio: Diphtheria toxoid 2 Lf, tetanus toxoid 5 Lf, acellular pertussis antigens [inactivated pertussis toxoid 2.5 mcg, filamentous hemagglutinin 5 mcg, pertactin 3 mcg, types 2 and 3 fimbriae 5 mcg], type 1 poliovirus 40 D-antigen units, type 2 poliovirus 8 D-antigen units, and type 3 poliovirus 32 D-antigen units per 0.5 mL (0.5 mL) [contains aluminum, neomycin sulfate, polymyxin B, polysorbate 80]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6215686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6215825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For I.M. use only, preferably in the deltoid; Adacel&reg;-Polio (Canadian availability) label recommends avoiding administration into the buttocks. Do not administer intradermally, I.V., or SubQ. Shake well prior to use; do not use unless a homogeneous, turbid, white suspension forms. Discard if the suspension is discolored or if there are cracks in the vial or syringe. Administer in the deltoid muscle of the upper arm. Do not administer additional vaccines or immunoglobulins at the same site, or using the same syringe.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC,  2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The use of licensed combination vaccines is generally preferred over separate injections of the equivalent components. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F6215817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with other vaccines or injections.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6215690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Kinrix&reg;: Active immunization against diphtheria, tetanus, pertussis, and poliomyelitis, used as the fifth dose in the DTaP series and the 4th dose in the IPV series",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for use as the fifth dose in the DTaP series and the fourth dose in the IPV series in children who received DTaP (Infanrix&reg;) and/or DTaP-Hepatitis B-IPV (Pediarix&reg;) as the first 3 doses and DTaP (Infanrix&reg;) as the fourth dose. Whenever feasible, the same manufacturer should be used to provide the pertussis component; however, vaccination should not be deferred if a specific brand is not known or is not available.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Adacel&reg;-Polio (Canadian availability): Active booster immunization against diphtheria, tetanus, pertussis, and poliomyelitis; alternative to fifth dose of DTaP-IPV; May be used for wound management when a tetanus toxoid-containing vaccine is needed for wound management [refer to current National Advisory Committee on Immunization (NACI) guidelines]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14790062\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Adacel&reg; (trade name for Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine) should not be confused with Adacel&reg;-Polio (trade name for Diphtheria and Tetanus Toxoids, Acellular Pertussis, and Poliovirus Vaccine in Canada)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6215808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adverse events reported within 4 days of vaccination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Drowsiness (19%, grade 3: 1%), fever (&ge;99.5&deg;F: 16%, &gt;100.4: 7%, &gt;104: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Loss of appetite (16%; grade 3: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site: Pain (57%; grade 3: 2%), redness (37%; &ge;50 mm: 18%, &ge;110 mm: 3%), arm circumference increase (36%, &gt;20 mm: 7%, &gt;30 mm: 2%), swelling (26%; &ge;50 mm: 10%, &ge;110 mm: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Cellulitis, cerebrovascular accident, constipation, dehydration, gastroenteritis, hypernatremia, injection site vesicles, pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Additional postmarketing events associated with Infanrix&reg;: Allergic reactions, anaphylactoid reactions, anaphylaxis, angioedema, apnea, hypotonic-hyporesponsive episode, lymphadenopathy, seizures, thrombocytopenia, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6215695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphtheria and tetanus toxoids, pertussis, poliovirus vaccine, or any component of the vaccine; encephalopathy occurring within 7 days of a previous pertussis vaccine not (not attributable to another identifiable cause); progressive neurologic disorders (including infantile spasms, uncontrolled epilepsy, or progressive encephalopathy)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6215696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Reactions from previous pertussis vaccination: Carefully consider use in patients with history of any of the following effects from previous administration of a pertussis-containing vaccine: Fever 40.5&deg;C (&ge;105&deg;F) within 48 hours of unknown cause; seizures with or without fever occurring within 3 days; persistent, inconsolable crying episodes lasting &ge;3 hours and occurring within 48 hours; shock or collapse (hypotonic-hyporesponsive episode [HHE]) occurring within 48 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Guillain-Barr&eacute; syndrome: Use with caution if Guillain-Barr&eacute; syndrome occurred within 6 weeks of prior tetanus toxoid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neurologic disorders: Use with caution in patients with history of seizure disorder, progressive neurologic disease, or conditions predisposing to seizures; ACIP and AAP guidelines recommend deferring immunization until health status can be assessed and condition stabilized. Antipyretics may be considered at the time of and for 24 hours following vaccination to patients at high risk for seizures to reduce the possibility of postvaccination fever.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP and the NACI recommend  simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adults: Safety and efficacy of Kinrix&reg; have not been established for use in adults.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established for use in children &lt;4 years of age (Kinrix&reg;; Adacel&reg;-Polio) and children &ge;7 years of age (Kinrix&reg;). If Kinrix&reg; is inadvertently administered to children &ge;7 years of age earlier than the fifth dose in the series, it may be counted as a valid dose, provided the minimum interval requirements were met.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Aluminum: Product may contain aluminum.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Latex: Packaging may contain natural latex rubber.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neomycin: Product may contain neomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Polymyxin B: Product may contain polymyxin B.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Polysorbate 80: Product may contain polysorbate 80.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6215812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6215691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6215692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted; Kinrix&reg; is not indicated for women of childbearing age. Adacel&reg;-Polio is not recommended for use in pregnant women unless a definite risk of pertussis exists.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6215694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Kinrix&reg; is not indicated for use in patients &ge;7 years of age. Use of Adacel&reg;-Polio in lactating women has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13908589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6215818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes active immunity to diphtheria, tetanus, pertussis, and poliovirus (types 1, 2 and 3) by inducing production of specific antibodies and antitoxins.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6215820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Immune response observed to all components ~1 month following vaccination",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Canadian Immunization Guide, Seventh Edition, 2006,&rdquo; Ottawa, ONT: Minister of Public Works and Government Services Canada, Public Health Agency of Canada, National Advisory Committee on Immunization, 2006. Available at file://www.phac-aspc.gc.ca/publicat/cig-gci/index.html",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/56/4998/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Licensure of a Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine and Guidance for Use as a Booster Dose,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(39):1078-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/56/4998/abstract-text/18830212 /pubmed\" id=\"18830212 \" target=\"_blank\">",
"        18830212",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) Regarding Routine Poliovirus Vaccination,&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 58(30):829-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/56/4998/abstract-text/19661857/pubmed\" id=\"19661857\" target=\"_blank\">",
"        19661857",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/56/4998/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?4/56/4998/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8974 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_4998=[""].join("\n");
var outline_f4_56_4998=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215528\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790063\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215688\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790522\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215824\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796187\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796188\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215828\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790523\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215686\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215825\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215817\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215690\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14790062\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215808\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215695\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215696\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299216\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215812\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215691\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215692\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215694\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13908589\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215818\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6215820\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8974\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8974|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/9/39060?source=related_link\">",
"      Diphtheria tetanus toxoids acellular pertussis inactivated poliovirus combination vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_56_4999="Hepatitis C and transfusion: A 'lookback' primer";
var content_f4_56_4999=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatitis C and transfusion: A 'lookback' primer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/56/4999/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/56/4999/contributors\">",
"     Joy L Fridey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/56/4999/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/56/4999/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/56/4999/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/56/4999/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/56/4999/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2000, primary care physicians, surgeons, and other medical specialists began receiving notification from hospital blood banks that a patient they had previously treated or were currently treating may have been exposed to hepatitis C virus (HCV) as a result of blood transfusion. This United States Public Health Service (USPHS)-mandated notification, developed in conjunction with the Food and Drug Administration (FDA), came as a surprise to practitioners, who were faced with the task of locating patients, informing them about the possible exposure, providing appropriate testing and counseling, and possibly evaluating or treating those who were found to be HCV positive, in a process referred to as \"lookback.\"",
"   </p>",
"   <p>",
"    Lookback encompasses the activities associated with tracing and notifying patients who may have received blood or blood components infected with transfusion-transmissible pathogens (TTP) from a previously infectious disease test-negative, but now positive, donor. Lookback is required for other TTPs such as HIV, but hepatitis C was unique because of the Federal government's highly prescriptive requirements for patient notification, which involved community physicians who cared for or were caring for these patients.",
"   </p>",
"   <p>",
"    Recognizing that involvement in an HCV lookback process is an infrequent and possibly new experience for many practitioners, the purpose of this discussion is to review the rationale for HCV lookback, define lookback, outline regulatory expectations, and provide physicians with resources that can make the patient notification process less onerous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GOVERNMENT RESPONSE TO THE HCV EPIDEMIC AND THE HISTORY OF HCV LOOKBACK",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that up to four million Americans are infected with HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of these individuals have been exposed to the virus through the sharing of needles used in injection drug use, and a smaller percentage through sexual contact, perinatally, or occupationally. Approximately one-third of infected people do not identifiably fall into these risk categories, but have a history of behavior, such as multiple sex partners, that places them at higher risk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transfusion transmission once accounted for 0.5 to 10 percent of HCV infections, but due to the use of increasingly sensitive blood donor screening assays, including nucleic acid testing (NAT), the HCV transfusion transmission risk is now about 1 per 2 million units. However, concerns remain within the FDA and the US Public Health Service that there is a population of individuals who may have been exposed to HCV through transfusions in the past.",
"   </p>",
"   <p>",
"    In 1997, the USPHS, which oversees the FDA and the Centers for Disease Control and Prevention (CDC), announced its intention to address the HCV epidemic. In response, the CDC launched a national prevention and control plan that included public education and other efforts to reach at-risk populations, an educational campaign directed at healthcare providers, and community-based prevention programs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Individuals who contracted HCV through transfusion were viewed as comprising a special subset of the \"at-risk\" population. Although it is recognized that the more general CDC outreach program may have identified some who acquired HCV through transfusion, the USPHS authorized the FDA to establish a \"targeted lookback\" program specifically to reach transfusion recipients.",
"   </p>",
"   <p>",
"    The approach to accomplishing this was described in the FDA's 1998 \"Guidance for Industry\" that required community blood banks and healthcare providers to take clearly defined actions that would make it possible to identify specific individuals who may have received contaminated blood. Responsibility for notifying potentially exposed patients was assigned primarily to the physician of record who had to make at least three attempts to contact the recipient and conduct other required notification activities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NEWEST HCV LOOKBACK RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the discovery of HCV in 1989 and the subsequent implementation of an HCV antibody detection assay for screening of blood donors in 1990, the risk of acquiring HCV through a blood transfusion was as high as 1 in 200 units. As a result of improvements in HCV antibody assays, and the introduction in 2002 of HCV nucleic acid testing (HCV NAT), the risk has fallen significantly (",
"    <a class=\"graphic graphic_table graphicRef69661 \" href=\"UTD.htm?30/59/31676\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. However, the prevalence of HCV among repeat donors is 12.3 per 100,000 donations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/8\">",
"     8",
"    </a>",
"    ], and, because new HCV infections are continually being identified in donors of previously negative units, lookback will continue to be required for the foreseeable future. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link&amp;anchor=H11#H11\">",
"     \"Laboratory testing of donated blood\", section on 'Hepatitis C virus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 2007, the FDA issued its fourth and final HCV lookback guidance document, based on \"improvements in the management and treatment of chronic hepatitis C\" that had occurred over time. Published in the Federal Register [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/9\">",
"     9",
"    </a>",
"    ], it applied a new lookback requirement for previous donations - going back as far as possible - from donors who tested positive on the first and least sensitive and least specific HCV EIA assay (version 1.0) that was licensed in 1990.",
"   </p>",
"   <p>",
"    The 2007 FDA requirements are still in effect and require \"reasonable\" attempts to notify the recipient by either the recipient's physician, legal guardian, or the healthcare facility (\"consignee\") that issued the unit for transfusion. The language for recipient notification is not as prescriptive as that in the 1998 FDA guidance, because it does not place the notification responsibility predominantly on the physician of record, and it does not explicitly state that \"three attempts\" must be made to notify the recipient. Although the 1998 FDA document was quite specific about how to carry out notification, in contrast, the newest guidance does not define what constitutes \"reasonable attempts\" to notify a recipient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL RATIONALE FOR HCV LOOKBACK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the risk of acquiring HCV from transfusion is now at extremely low levels, early CDC estimates that 300,000 individuals in the United States had HCV as a result of blood transfusion spurred government action [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/10\">",
"     10",
"    </a>",
"    ]. An August 1997 Department of Health and Human Services (HHS) memorandum, recapitulating a Congressional report on Government Reform and Oversight, stated that HHS should implement actions to notify previously transfused individuals \"so that they might seek diagnosis and treatment\" [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/4\">",
"     4",
"    </a>",
"    ]. The lookback experience of Canadian and European blood centers had already demonstrated that the process was successful in finding patients who contracted HCV from transfusions (",
"    <a class=\"graphic graphic_table graphicRef61796 \" href=\"UTD.htm?43/16/44299\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/11-15\">",
"     11-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concern over the need for diagnosis is derived from the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronicity occurs in 85 percent of those exposed; cirrhosis develops, usually insidiously, in approximately 50 percent of such patients after a mean time of 20 to 30 years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"       \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of extrahepatic conditions are associated with HCV infection, including essential mixed cryoglobulinemia, arthritis, and glomerular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=see_link\">",
"       \"Extrahepatic manifestations of hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hepatocellular carcinoma, which almost exclusively occurs in patients with cirrhosis, develops at a rate of 1.5 to 2 percent per year in these patients (",
"      <a class=\"graphic graphic_figure graphicRef53256 \" href=\"UTD.htm?26/21/26973\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"       \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link\">",
"       \"Epidemiology and etiologic associations of hepatocellular carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Particularly ominous is the fact that HCV infection is often occult and these complications insidious [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Only one-third of patients exhibit symptoms, and most of these are constitutional in nature; icterus is rare and even liver function test abnormalities, such as elevated serum alanine aminotransferase (ALT) concentrations, do not occur with reliable frequency. Thus, overt symptoms that normally would alert a physician or compel most patients to seek medical care are conspicuously absent in HCV-infected persons. As a result, hepatic injury can progress undetected for decades.",
"   </p>",
"   <p>",
"    Concerns about the serious sequelae of HCV infection and increasing optimism that many individuals may benefit from antiviral therapy (eg, interferon alfa plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ) have prompted the government to institute this patient identification and notification program. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HCV LOOKBACK FURTHER DEFINED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strictly speaking, lookback is the process through which patients who may have received pathogen-infected blood are identified by tracing a suspect donor's previous donations back to those specific recipients. Transfusion recipients who are the \"targets\" of HCV lookback are those who have been transfused with blood from a now HCV-positive donor who either had not been previously tested for HCV or who was negative for HCV at the time of previous donations.",
"   </p>",
"   <p>",
"    Under the FDA's 1998 and 2007 recommendations, the community blood center that detects a donor's HCV infection is required to provide the acquiring hospitals with a list of the donor's previous units [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/5,9\">",
"     5,9",
"    </a>",
"    ]. The hospital transfusion service is required to search its records to determine who received the units and notify the \"recipient's physician of record\" or attempt to directly contact the patient. Although the FDA uses the words \"recommendation\" and \"guidance\" in the context of HCV lookback, participation is not considered to be optional.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSICIAN ROLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a transfusion service has been notified about suspect units, the hospital or physician has a total of 12 weeks to complete the patient notification process. The regulations do not make specific recommendations about the manner in which notification must take place, but this author recommends that it be done in such a way that each attempt can later be proven (eg, certified mail, return receipt requested; documented phone calls). Notification attempts should be documented in the patient's medical or transfusion service records. It should also be documented if the patient has died or cannot be located. If the patient is incompetent, the physician should consider notifying the legally designated representative; if the patient is a minor, the legal guardian should be contacted.",
"   </p>",
"   <p>",
"    Information about how patients can be located, what follow-up tests should be ordered, and information for patients are discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Locating the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient is no longer on record or if records are not available, credit report companies can often provide location services. For a nominal fee (which may include subscription charges), companies like Experian (www.experian.com), Trans Union (www.transunion.com), or Equifax (www.equifax.com) can provide a recent address if information such as the social security number and name are given by the requester. It also may be possible to locate someone through various Internet search engines. At a minimum, first and last names are needed to launch the search. The search can be narrowed if the individual's geographic location is also provided.",
"   </p>",
"   <p>",
"    Several Web sites that access the Social Security Death Index contain death record information. These sites, which include www.familytreemaker.com and www.ancestry.com, may be of use if it is believed that the person may have died. The regional public health department is another potential resource. Finally, it may be helpful to engage the assistance of the hospital transfusion service or accounting department; the latter probably subscribes to at least one of the major credit services.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tests for HCV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriate HCV testing consists of an antibody screening assay, the HCV EIA, and, if reactive, a follow-up supplemental (or \"confirmatory\") test. An FDA-licensed supplemental test, called the recombinant immunoblot assay (RIBA) is considered the appropriate follow-up assay to a reactive EIA to exclude a false positive result. Tests that probe for viral genetic material, such as HCV nucleic acid testing (HCV NAT) may also be clinically useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=see_link\">",
"     \"Screening for and diagnosis of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Physician and patient information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recipient notification does not just involve telling the patient that he or she may have received contaminated blood. Notification would also include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A basic explanation of the need for HCV testing and counseling.",
"     </li>",
"     <li>",
"      Sufficient written or oral information so the patient can make an informed decision about whether to undergo testing and receive counseling.",
"     </li>",
"     <li>",
"      Information about facilities or programs where the patient can undergo testing; the notifying physician may provide testing, but is not required to do so.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A wealth of HCV information is available through the CDC and other public health websites (",
"    <a class=\"graphic graphic_table graphicRef52050 \" href=\"UTD.htm?6/53/7004\">",
"     table 3",
"    </a>",
"    ). Although the lookback guidelines do not specify exactly what information patients should be given, it would be appropriate that at least several issues be addressed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon the donor's test results, an estimate of the chance that HCV was transmitted to the patient by the unit in question (",
"      <a class=\"graphic graphic_table graphicRef73098 \" href=\"UTD.htm?3/15/3323\">",
"       table 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The clinical outcomes of HCV infection and available treatments as mentioned above. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"       \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"       \"Overview of the management of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The risk of household [",
"      <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/23\">",
"       23",
"      </a>",
"      ], sexual [",
"      <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/23-25\">",
"       23-25",
"      </a>",
"      ], and perinatal transmission [",
"      <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/26,27\">",
"       26,27",
"      </a>",
"      ] (uncommon for the first, small but real for the second and third) and suggestions for the prevention of transmission. The likelihood of sexual or perinatal transmission in increased in patients who are also infected with HIV. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=see_link\">",
"       \"Epidemiology and transmission of hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The need to avoid alcohol, due to its association with a more severe prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/17,28\">",
"       17,28",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations and natural history of chronic hepatitis C virus infection\", section on 'Alcohol intake'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Written information that is easily available for patients can be obtained through the American Liver Foundation (",
"    <a class=\"external\" href=\"file://www.liverfoundation.org/\">",
"     www.liverfoundation.org",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=see_link\">",
"     \"Patient information: Hepatitis C (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HCV LOOKBACK RESULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the earliest publications on the effectiveness of HCV lookback demonstrated that, in 314 recipients of units from donors who subsequently tested positive for HCV, approximately 80 percent of the adult and 43 percent of the pediatric patients had died. However, among all patients, the percentage of HCV infections deemed attributable to transfusion was in the range of 4 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a massive Canadian lookback program which involved attempts to notify over 100,000 individuals who received blood between 1982 and 1990, 4.1 percent of the approximately 51,000 recipients tested were HCV positive; newly diagnosed cases, presumed due to transfusion, represented 42 to 58 percent of the total [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. In a lookback targeted at all 1980 to 1992 blood recipients from an Alaskan medical center, approximately 1.3 percent of 3169 patients were infected with HCV; 5 percent of 764 tested patients were HCV positive [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A single institution lookback study was performed in infants and children transfused with blood and blood products between 1982 and 1992 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/33\">",
"     33",
"    </a>",
"    ]. Of the 5473 eligible patients, 4726 were locatable and 2758 were tested. A new diagnosis of HCV infection was confirmed in 1.6 percent (43 cases) of those tested.",
"   </p>",
"   <p>",
"    These studies demonstrated that, although time-consuming, lookback programs were successful in identifying some patients who likely were infected with HCV through transfusion, but unaware of their exposure.",
"   </p>",
"   <p>",
"    The current sensitivity of HCV assays has not only significantly decreased the risk of transfusion-transmitted HCV, but has also made it less likely that, in the future, a substantial number of transfusion-transmitted HCV infections would be found through large scale, public health-driven lookback initiatives. This has been demonstrated by a Canadian survey, which reported that only 0.8 percent additional, \"plausible\" cases of transfusion-transmitted HCV infection were found through public health notification programs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/4999/abstract/34\">",
"     34",
"    </a>",
"    ]. However, for the individual patient who has received blood from a now HCV-positive donor, lookback and recipient notification programs are an important part of post-transfusion care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CONCLUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients identified though HCV lookback will benefit from the opportunity to undergo testing and treatment for this potentially devastating disease. Although participation in patient notification is a novel experience for many practitioners, resources that can make these efforts successful &mdash; and perhaps not so onerous &mdash; are readily available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hepatitis C virus (HCV) lookback program exists because concerns remain within the FDA and the US Public Health Service that there is a population of individuals who may have been exposed to HCV through transfusions in the past.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     What is HCV lookback",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lookback is the process through which patients who may have received pathogen-infected blood are identified by tracing a suspect donor's previous donations back to those specific recipients. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'HCV lookback further defined'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Who are the targets for HCV lookback",
"    </span>",
"    &nbsp;&mdash;&nbsp;Targets of HCV lookback are those who have been transfused with blood from a now HCV-positive donor who either had not been previously tested for HCV or who was negative for HCV at the time of previous donations. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical rationale for HCV lookback'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     What are the clinician's responsibilities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 FDA requirements require \"reasonable\" attempts to notify the recipient by either the recipient's physician, legal guardian, or the healthcare facility (\"consignee\") that issued the unit for transfusion. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Newest HCV lookback recommendations'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'Locating the patient'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The patient, once located, must be notified that he or she may have received contaminated blood. Notification should also include the following. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Physician and patient information'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An explanation of the need for HCV testing and counseling and sufficient written or oral information to make an informed decision about whether to undergo testing and receive counseling.",
"     </li>",
"     <li>",
"      Information about facilities or programs where the patient can undergo testing for HCV.",
"     </li>",
"     <li>",
"      Information about the long-term risks of HCV infection, its treatment, risks of transmission, and suggestions for the prevention of transmission.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     www.cdc.gov/hepatitis/HCV/index.htm (Accessed on March 24, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/2\">",
"      Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26:62S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/3\">",
"      Alter MJ, Hadler SC, Judson FN, et al. Risk factors for acute non-A, non-B hepatitis in the United States and association with hepatitis C virus infection. JAMA 1990; 264:2231.",
"     </a>",
"    </li>",
"    <li>",
"     Alter MJ. Public Health Service, Centers for Disease Control and Prevention. August 22, 1997 Memorandum.",
"    </li>",
"    <li>",
"     Guidance for Industry. Current Good Manufacturing Practice of Blood and Blood Components: (1) Quarantine and Disposition of Units from Prior Collections from Donors with Repeatedly Reactive Screening Tests for Antibody to Hepatitis C Virus (Anti-HCV); (2) Supplemental Testing, and the Notification of Consignees and Blood Recipients of Donor Test Results for Anti-HCV. US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research Center, September, 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/6\">",
"      Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/7\">",
"      Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/8\">",
"      Wang B, Schreiber GB, Glynn SA, et al. Does prevalence of transfusion-transmissible viral infection reflect corresponding incidence in United States blood donors? Transfusion 2005; 45:1089.",
"     </a>",
"    </li>",
"    <li>",
"     Current Good Manufacturing Practice for Blood and Blood Components; Notification of Consignees and Transfusion Recipients Receiving Blood and Blood Products at Increased Risk of Transmitting Hepatitis C Infection; Final Rule. Federal Register, 72(160), August 24, 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/10\">",
"      Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/11\">",
"      Wall A, Lau W, Lewis J, et al. Hepatitis C virus (HCV) targeted lookback program. Transfusion 1997; 37:98S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/12\">",
"      Christensen PB, Groenbaek K, Krarup HB. Transfusion-acquired hepatitis C: the Danish lookback experience. The Danish HCV [hepatitis C virus] Lookback Group. Transfusion 1999; 39:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/13\">",
"      Vrielink H, van der Poel CL, Reesink HW, et al. Look-back study of infectivity of anti-HCV ELISA-positive blood components. Lancet 1995; 345:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/14\">",
"      Lau W, Bischochio M, Poon A. Hepatitis C targeted lookback in pediatric patients. Transfusion 1997; 37:99S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/15\">",
"      Goldman M, Juodvalkis S, Gill P, Spurll G. Hepatitis C lookback. Transfus Med Rev 1998; 12:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/16\">",
"      Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995; 332:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/17\">",
"      Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/18\">",
"      Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med 1995; 123:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/19\">",
"      Koff RS, Dienstag JL. Extrahepatic manifestations of hepatitis C and the association with alcoholic liver disease. Semin Liver Dis 1995; 15:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/20\">",
"      Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. N Engl J Med 1992; 327:1906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/21\">",
"      Di Bisceglie AM, Order SE, Klein JL, et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am J Gastroenterol 1991; 86:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/22\">",
"      Di Bisceglie AM, Goodman ZD, Ishak KG, et al. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 1991; 14:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/23\">",
"      Everhart JE, Di Bisceglie AM, Murray LM, et al. Risk for non-A, non-B (type C) hepatitis through sexual or household contact with chronic carriers. Ann Intern Med 1990; 112:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/24\">",
"      Dienstag JL. Sexual and perinatal transmission of hepatitis C. Hepatology 1997; 26:66S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/25\">",
"      Alter MJ, Coleman PJ, Alexander WJ, et al. Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. JAMA 1989; 262:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/26\">",
"      Ohto H, Terazawa S, Sasaki N, et al. Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med 1994; 330:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/27\">",
"      Resti M, Azzari C, Mannelli F, et al. Mother to child transmission of hepatitis C virus: prospective study of risk factors and timing of infection in children born to women seronegative for HIV-1. Tuscany Study Group on Hepatitis C Virus Infection. BMJ 1998; 317:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/28\">",
"      Wiley TE, McCarthy M, Breidi L, et al. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 1998; 28:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/29\">",
"      Menozzi D, Udulutch T, Llosa AE, Galel SA. HCV lookback in the United States: effectiveness of an extended lookback program. Transfusion 2000; 40:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/30\">",
"      Bowker SL, Smith LJ, Rosychuk RJ, Preiksaitis JK. A review of general hepatitis C virus lookbacks in Canada. Vox Sang 2004; 86:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/31\">",
"      Goldman M, Patterson L, Long A. Recent Canadian experience with targeted hepatitis C virus lookback. Transfusion 2006; 46:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/32\">",
"      Williams JL, Cagle HH, Christensen CJ, et al. Results of a hepatitis C general transfusion lookback program for patients who received blood products before July 1992. Transfusion 2005; 45:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/33\">",
"      Luban NL, Colvin CA, Mohan P, Alter HJ. The epidemiology of transfusion-associated hepatitis C in a children's hospital. Transfusion 2007; 47:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/4999/abstract/34\">",
"      Whitlock M, Lord S, Buxton JA, et al. Evaluating the impact of public health notification of suspected transfusion-transmissible hepatitis C virus infection and effectiveness of lookback and traceback investigations by Canadian Blood Services in British Columbia, Canada, August 2002 through February 2005. Transfusion 2007; 47:1534.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7944 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_4999=[""].join("\n");
var outline_f4_56_4999=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GOVERNMENT RESPONSE TO THE HCV EPIDEMIC AND THE HISTORY OF HCV LOOKBACK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NEWEST HCV LOOKBACK RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL RATIONALE FOR HCV LOOKBACK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HCV LOOKBACK FURTHER DEFINED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSICIAN ROLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Locating the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tests for HCV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Physician and patient information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HCV LOOKBACK RESULTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CONCLUSIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      What is HCV lookback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Who are the targets for HCV lookback",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      What are the clinician's responsibilities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7944\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7944|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/21/26973\" title=\"figure 1\">",
"      Hepatocellular Ca hep C",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7944|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/59/31676\" title=\"table 1\">",
"      Infection risk of blood products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/16/44299\" title=\"table 2\">",
"      HCV lookback at blood centers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/53/7004\" title=\"table 3\">",
"      HCV information resources",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/15/3323\" title=\"table 4\">",
"      HCV and blood test results",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41849?source=related_link\">",
"      Screening for and diagnosis of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_56_5000="Sacroiliitis in IBD MRI";
var content_f4_56_5000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F69296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F69296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sacroiliitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 338px; height: 748px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Upper panel) Coronal T1-weighted MRI of the sacroiliac joints reveals decreased signal in the sacrum and the iliac in the region of the inferior left sacroiliac joint (arrows). (Middle panel) Coronal T2- weighted MRI reveals corresponding hyperintense signal in the inferior left sacroiliac joint (arrows). (Bottom panel) Axial T1- weighted MRI with fat saturation following intravenous gadolinium injection demonstrates intense enhancement of the left sacroiliac joint. These findings are most compatible with sacroiliitis in a patient with inflammatory bowel disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Doug Brown, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_5000=[""].join("\n");
var outline_f4_56_5000=null;
var title_f4_56_5001="Pulmonary coccidioidomycosis";
var content_f4_56_5001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary coccidioidomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 586px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Chest radiograph shows consolidation in right lower lung zone (arrow) and right hilar enlargement (arrowhead).",
"    <br>",
"     (B) Mediastinal window of contrast-enhanced computed tomography (CT) (5-mm collimation) scan obtained at the level of bronchus intermedius shows enlarged right hilar (arrowhead), subcarinal, and paraesophageal lymph nodes (arrows).",
"     <br>",
"      (C) CT scan obtained at the level of the right middle lobe bronchus shows parenchymal consolidation in the right middle lobe and enlarged subcarinal lymph nodes (arrows).",
"      <br>",
"       (D) Photomicrograph of the surgical biopsy specimen shows granulomatous inflammation and fibrosis with infiltration of multinucleated giant cells, eosinophils, and lymphocytes (Hematoxylin and Eosin stain, x100).",
"       <br>",
"        (E) Photomicrograph shows a yeast form developing a spherule of Coccidioides immitis (arrow), which is engulfed by a multinucleated giant cell (arrowheads). The periodic acid-Schiff stain highlights its thick yeast wall (Periodic acid-Schiff stain, x400). The patient was a 58-year-old man with a 1 month history of dyspnea and fever.",
"        <div class=\"footnotes\">",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced with permission from: Fungal and parasitic infections. In: Imaging of pulmonary infections. Muller NL, Franquet T, Kyung SL (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2007. Copyright &copy; 2007 Lippincott Williams &amp; Wilkins.",
"        </div>",
"        <div class=\"contractual\">",
"         <br/>",
"         <a href=\"file://www.lww.com\">",
"          file://www.lww.com",
"         </a>",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_5001=[""].join("\n");
var outline_f4_56_5001=null;
var title_f4_56_5002="Treatment of acute exacerbations of asthma in adults";
var content_f4_56_5002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute exacerbations of asthma in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/56/5002/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/56/5002/contributors\">",
"     Christopher H Fanta, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/56/5002/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/56/5002/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/56/5002/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/56/5002/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/56/5002/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best strategy for management of acute exacerbations of asthma is early recognition and intervention, before attacks become severe and potentially life threatening. Detailed investigations into the circumstances surrounding fatal asthma have frequently revealed failures on the part of both patients and clinicians to recognize the severity of the disease and to intensify treatment appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Asthma Expert Panel has published useful algorithms on the management of acute exacerbations of asthma, both in the home and acute care settings (",
"    <a class=\"graphic graphic_algorithm graphicRef56621 \" href=\"UTD.htm?19/23/19829\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80100 \" href=\"UTD.htm?25/62/26600\">",
"     algorithm 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. These algorithms may be used for asthma exacerbations of any severity. A table outlining the emergency management of severe asthma exacerbations in adults is provided (",
"    <a class=\"graphic graphic_table graphicRef54125 \" href=\"UTD.htm?32/57/33693\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The basic principles of care are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assess the severity of the attack",
"     </li>",
"     <li>",
"      Use inhaled short-acting beta agonists early and frequently and consider concomitant use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      for severe exacerbations",
"     </li>",
"     <li>",
"      Start systemic glucocorticoids if there is not an immediate and marked response to the inhaled short-acting beta agonists",
"     </li>",
"     <li>",
"      Make frequent (every one to two hours) objective assessments of the response to therapy until definite, sustained improvement is documented",
"     </li>",
"     <li>",
"      Admit patients who do not respond well after four to six hours to a setting of high surveillance and care",
"     </li>",
"     <li>",
"      Educate patients about the principles of self-management for early recognition and treatment of a recurrent attack and develop an \"asthma action plan\" for recurrent symptoms (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"       \"What do patients need to know about their asthma?\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The management of acute asthma exacerbations will be presented here. Mechanical ventilation in severe exacerbations of asthma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=see_link\">",
"     \"Invasive mechanical ventilation in adults with acute exacerbations of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL RESPONSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instructions to a patient regarding self-administration of medications and self-monitoring differ depending upon the patient's history (eg, medications currently used to treat asthma, prior history of severe exacerbations, and prior experience with oral glucocorticoids) and ability to understand and follow directions. An individualized written \"asthma action plan\" that is based upon symptoms and peak flow measurements can be provided to patients to provide clear instructions on how to detect and respond to changes in symptoms and peak flow readings (",
"    <a class=\"graphic graphic_form graphicRef55900 \" href=\"UTD.htm?36/39/37498\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. Peak flow meters are available at low cost (eg, $30 or less).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Detecting the onset of an exacerbation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients are very sensitive to increased asthma symptoms, while others perceive reduced airflow only when it becomes marked. For the latter group, a decrease in peak expiratory flow may be the first sign that asthma control is deteriorating. A decrement in peak flow of greater than 20 percent from normal, or from the patient's personal best value, signals the presence of a deterioration and helps one gauge the severity of the change. A fall to less than 50 percent of baseline should be considered a severe attack. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When patients recognize the onset of an exacerbation, they should self-administer an inhaled short-acting beta agonist as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two to six (depending upon the dose that is typically effective and tolerated by that individual) puffs from a metered dose inhaler. This can be repeated in 20 minutes, or",
"     </li>",
"     <li>",
"      A nebulized treatment, repeated after approximately 20 minutes, if needed",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient should then repeat a peak flow measurement. Based upon the initial response to the inhaled beta agonist, the patient should either continue self-care or seek medical attention, as described below (",
"    <a class=\"graphic graphic_algorithm graphicRef56621 \" href=\"UTD.htm?19/23/19829\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Good response to initial home treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the repeat peak flow measurement increases to above 80 percent of the patient's personal best, then the patient may safely continue self-treatment (",
"    <a class=\"graphic graphic_algorithm graphicRef56621 \" href=\"UTD.htm?19/23/19829\">",
"     algorithm 1",
"    </a>",
"    ). Other important early interventions include removal of or from the offending stimulus (if known), continued administration of inhaled short-acting beta agonists, and consideration of a short course of oral glucocorticoids if beta agonists do not fully correct the decrement in peak flow.",
"   </p>",
"   <p>",
"    Quadrupling the dose of inhaled glucocorticoids in the setting of mildly increased asthma symptoms, rather than initiating oral glucocorticoids, may be of some benefit, although this approach has not been studied sufficiently [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/4\">",
"     4",
"    </a>",
"    ]. Doubling the dose of inhaled glucocorticoids appears to be ineffective and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. In a well-executed double blind placebo controlled trial of 390 patients with asthma, subjects were randomly assigned to treatment with twice their usual dose of inhaled glucocorticoid or placebo (delivered using an identical inhaler) when asthmatic symptoms worsened [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/5\">",
"     5",
"    </a>",
"    ]. Over the course of the one-year study, over half of all patients experienced an episode of worsening of their asthma, and 12 percent eventually required systemic glucocorticoid therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    to control their symptoms. There was no significant difference in the need for systemic glucocorticoid therapy between groups, suggesting that, in general, doubling the inhaled glucocorticoid dosage in the acute setting has little clinical impact on the progression of an acute exacerbation.",
"   </p>",
"   <p>",
"    The patient should initiate contact with the clinician for instructions about how to continue care. The asthma action plan should include clear instructions about how to reach the clinician during exacerbations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Incomplete response to initial home treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with an incomplete response to inhaled short-acting bronchodilator, if the repeat peak flow measurement increases to the range of 50 to 79 percent of the patient's personal best, then the patient should initiate oral glucocorticoids and contact the clinician urgently for advice (",
"    <a class=\"graphic graphic_algorithm graphicRef56621 \" href=\"UTD.htm?19/23/19829\">",
"     algorithm 1",
"    </a>",
"    ). Other early interventions include removal of or from the offending stimulus (if known), continued administration of inhaled short-acting beta agonists, and intermittent measurements of peak flow to assess response.",
"   </p>",
"   <p>",
"    Timely administration of oral glucocorticoids for serious asthmatic exacerbations is probably the single most effective strategy for reducing emergency department visits and hospitalizations for acute asthmatic attacks. Patients with serious exacerbations frequently require evaluation in the office, and may need to proceed to the emergency department if improvement is not apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Poor response to initial home treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should seek immediate medical attention if they have a peak expiratory flow rate that remains less than 50 percent of baseline, symptoms or signs of severe exacerbation (eg, marked breathlessness), or are at high risk for a fatal attack. Inhaled beta agonists should continue to be administered while help is arriving. Risk factors for a fatal asthma attack include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous severe exacerbation (eg, intubation or ICU admission)",
"     </li>",
"     <li>",
"      Two or more hospitalizations for asthma in the past year",
"     </li>",
"     <li>",
"      Three or more emergency department visits for asthma in the past year",
"     </li>",
"     <li>",
"      Hospitalization or emergency department visit for asthma in the past month",
"     </li>",
"     <li>",
"      Use of more than two canisters of short-acting beta agonist per month",
"     </li>",
"     <li>",
"      Difficulty perceiving asthma symptoms or severity of exacerbations",
"     </li>",
"     <li>",
"      Low socioeconomic status, inner city residence, illicit drug use, major psychosocial problems",
"     </li>",
"     <li>",
"      Comorbidities, such as cardiovascular, chronic lung, or psychiatric disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SEVERITY ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the patient presents for evaluation, a number of clinical findings and objective tests may assist the clinician in assessing the severity of an asthma attack (",
"    <a class=\"graphic graphic_algorithm graphicRef80100 \" href=\"UTD.htm?25/62/26600\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of certain clinical findings may help to identify patients having severe asthma attacks. Pulsus paradoxus (ie, a fall in systolic blood pressure by at least 12 mmHg during inspiration), use of accessory muscles of inspiration (eg, sternocleidomastoid muscles), diaphoresis, and inability to lie supine due to breathlessness all are indicative of severe airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/6\">",
"     6",
"    </a>",
"    ]. Unfortunately, these findings are not sensitive indicators of severe attacks; up to 50 percent of patients with severe airflow obstruction will not manifest any of these abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Peak flow",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of expiratory airflow with a peak flow meter (or spirometer) is the best method for objective assessment of the severity of an asthma attack. Peak flow measurements take less than one minute to perform, are safe and inexpensive, and, when repeated over time, can be used to monitor a patient's response to treatment. They are also useful as a predictive marker for the possibility of hypercapnia, as discussed below. Normal values differ with gender, height, and age (",
"    <a class=\"graphic graphic_table graphicRef57257 graphicRef62839 graphicRef64420 \" href=\"UTD.htm?35/36/36430\">",
"     table 2A-C",
"    </a>",
"    ), but a peak flow rate below 200",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    indicates severe obstruction for all but unusually small adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"     \"Peak expiratory flow rate monitoring in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Gas exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Marked hypoxemia (arterial partial pressure of oxygen [PaO",
"    <sub>",
"     2",
"    </sub>",
"    ] &lt;60 mmHg [8 kPa], oxygen saturation [SaO",
"    <sub>",
"     2",
"    </sub>",
"    ] &lt;90 percent) is infrequent during asthma attacks; however, it remains a potential cause of severe complications and death. The ready availability of transcutaneous oximetry (ie, pulse oximetry) allows noninvasive screening for hypoxemia among patients with severe asthma attacks. Current guidelines recommend the use of transcutaneous pulse oximetry monitoring particularly among patients who are in severe distress, have a forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) or peak expiratory flow that is less than 40 percent of baseline, or are unable to perform lung function measures [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. There is no contraindication to the use of continuous transcutaneous oximetry during all asthmatic attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Assessing hypercapnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of arterial partial pressure of carbon dioxide (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) is important in patients with a severe asthma attack. Respiratory drive is almost invariably increased in acute asthma, resulting in hyperventilation and a correspondingly decreased PaCO",
"    <sub>",
"     2",
"    </sub>",
"    . Thus, an elevated or even normal PaCO",
"    <sub>",
"     2",
"    </sub>",
"    indicates that airway narrowing is so severe that the respiratory system cannot respond adequately to the output of the respiratory center. Hypercapnia and respiratory failure can then develop rapidly with any further airway obstruction or with respiratory muscle fatigue.",
"   </p>",
"   <p>",
"    Simple peak flow measurements provide a useful screening tool for the possibility of hypercapnia (in contrast to hypoxemia) and obviate the need for routine arterial blood gases in acutely ill patients. In the absence of respiratory depressant medications such as narcotics or sedatives, hypercapnia occurs only when the peak expiratory flow falls below 25 percent of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Thus, arterial blood gas measurements in acute asthma are generally indicated only among patients with persistent dyspnea (despite initial bronchodilator therapy) whose peak expiratory flow remains below 25 percent of normal. They may also be necessary in the patient who is too ill to perform a peak flow measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest radiographs are generally unrevealing in acute asthma attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/10\">",
"     10",
"    </a>",
"    ]. The most common abnormality is pulmonary hyperinflation. Other abnormal findings (eg, pneumothorax, pneumomediastinum, pneumonia, or atelectasis) are infrequent, occurring in only about 2 percent of chest radiographs obtained among patients presenting to emergency departments for the treatment of acute asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, chest radiographs in patients hospitalized for their asthma can be limited to those patients with suspected complications (eg, temperature &gt;38.3&ordm;C, unexplained chest pain, leukocytosis, or hypoxemia). They are also useful for patients at high risk for comorbidities (eg, based upon a history of intravenous drug abuse, immunosuppression, granulomatous disease, recent seizures, cancer, chest surgery, or heart failure) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/10,13\">",
"     10,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A table outlining the emergency management of severe asthma exacerbations in adults is provided (",
"    <a class=\"graphic graphic_table graphicRef54125 \" href=\"UTD.htm?32/57/33693\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The primary goals of therapy for acute severe asthma are the rapid reversal of airflow obstruction and the correction, if necessary, of severe hypercapnia or hypoxemia. Airflow obstruction is most rapidly alleviated by the combination of repeated administration of inhaled bronchodilators and early institution of systemic glucocorticoids (",
"    <a class=\"graphic graphic_algorithm graphicRef56621 \" href=\"UTD.htm?19/23/19829\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef80100 \" href=\"UTD.htm?25/62/26600\">",
"     algorithm 2",
"    </a>",
"    ). Until their respiratory distress has abated, patients should receive close monitoring, including serial measurements of lung function (eg, peak expiratory flow), to assess the response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Inhaled beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mainstay of bronchodilator treatment is inhalation of short-acting beta-2-selective adrenergic agonists, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19812?source=see_link\">",
"     metaproterenol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20372?source=see_link\">",
"     pirbuterol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3,14\">",
"     3,14",
"    </a>",
"    ]. The standard regimen for initial care in the emergency department has become albuterol (or an equivalent) 2.5 to 5 mg by continuous flow (also called \"hand-held\" or \"updraft\") nebulization every 20 minutes for three doses, then 2.5 to 10 mg every one to four hours as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. Another protocol calls for administration of albuterol by MDI with a spacer, four puffs every 10 minutes, or eight puffs every 20 minutes, for up to four hours, then every one to four hours as needed. For critically ill patients, some clinicians prefer continuous nebulization, administering 10 to 15 mg over one hour. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Nebulizer versus MDI",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relatively large particle size generated by continuous flow nebulizers and the loss of medication from the expiratory port of the nebulizer system make this method of delivery relatively inefficient compared to a metered dose inhaler (MDI). Comparisons of MDI plus spacer systems (eg, Aerochamber, Optichamber, Vortex, and others) to nebulizer delivery, using the same beta agonist but in much reduced doses, have demonstrated comparable improvements in lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, one prospective but unblinded trial analyzed data from 2342 emergency department visits by 1420 patients and noted that admission rates were the same in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    by nebulizer or by MDI with a spacer [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/18\">",
"     18",
"    </a>",
"    ]. Furthermore, MDI treatment was associated with significantly shorter emergency department stays (164 versus 175 minutes), greater improvements in peak flow (127 versus 112",
"    <span class=\"nowrap\">",
"     L/min),",
"    </span>",
"    and a lower cumulative dose of albuterol (1125 mcg versus 6700 mcg).",
"   </p>",
"   <p>",
"    Four to six carefully administered inhalations from an MDI with spacer have generally been found to equal one nebulizer treatment, although the equivalent dose has not been precisely defined. In comparative trials, administration of beta agonist by MDI with spacer was directly supervised to ensure the patient's proper coordination and inhalational technique.",
"   </p>",
"   <p>",
"    Many emergency departments (including our own) continue to rely on nebulized administration of beta agonists for acutely ill asthmatic patients, taking advantage of the simplicity of delivery during the patient's tidal breathing. Nevertheless, one implication of equivalency of the two delivery methods is that maximal bronchodilator therapy can be delivered using routinely available supplies in the home or clinician's office, even without availability of a compressor and nebulizer. In addition, as patients recover in the hospital from acute, severe attacks, the transition can be made from nebulized beta agonists to beta agonists by MDI with spacer without loss of efficacy and with the opportunity for patient education in proper inhaler technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Inhaled anticholinergics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most recent guidelines for asthma management prepared by the Expert Panel of the National Asthma Education and Prevention Program (Expert Panel Report III) recommend the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    for patients with severe exacerbations who are in the emergency department, but not during hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adult dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    for nebulization is 500 mcg every 20 minutes for three doses, then as needed [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. Alternatively, ipratropium can be administered by MDI at a dose of eight inhalations every 20 minutes, then as needed for up to three hours.",
"   </p>",
"   <p>",
"    Some investigators have reported that the combination provides greater bronchodilation than beta agonists alone, particularly among patients with the most severe airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Meta-analyses also have supported the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    in the setting of very severe airflow obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20870?source=see_link\">",
"     \"Anticholinergic agents in the management of acute exacerbations of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, positive findings have not been universal. As examples, a 1996 multicenter trial involving more than 300 adults treated in emergency departments for asthma exacerbations could find no advantage to combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    over albuterol alone, either for the entire population of patients or for any identifiable subgroups [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/25\">",
"     25",
"    </a>",
"    ]. A second trial of 254 patients also failed to demonstrate any benefit from the addition of ipratropium during acute attacks of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/26\">",
"     26",
"    </a>",
"    ]. This controversy continues with the conflicting results of a large trial conducted in New Zealand, in which for the group as a whole, greater bronchodilation was achieved with the combined use of albuterol and ipratropium, but no advantage could be found among those with the most severe obstruction (FEV",
"    <sub>",
"     1",
"    </sub>",
"    &lt;1 L) on presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At present, the use of inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     ipratropium",
"    </a>",
"    is usually reserved for patients with severe airflow obstruction failing to improve despite repeated administration of inhaled beta agonists. Other special circumstances in which such parasympatholytic therapy may be of particular benefit include treatment of patients on monoamine oxidase inhibitor therapy (who may have increased toxicity from sympathomimetic therapy due to impaired drug metabolism), patients with chronic obstructive pulmonary disease with an asthmatic component, and patients whose asthma has been triggered by beta-blocker therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with continued wheezing and shortness of breath despite intensive bronchodilator therapy most likely have persistent airflow obstruction on the basis of airway inflammation and intraluminal mucus plugging. Their rate of improvement typically slows after the first hour of treatment, since airway edema, cellular infiltration, and mucus hypersecretion resolve with a tempo far slower than smooth muscle constriction [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/28\">",
"     28",
"    </a>",
"    ]. Among patients with significant airflow obstruction despite intensive treatment with bronchodilators, systemic glucocorticoids speed the rate of improvement [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current guidelines encourage early systemic glucocorticoids for all patients who have a moderate (peak expiratory flow &lt;70 percent of baseline) or severe exacerbation (peak expiratory flow &lt;40 percent of baseline; in the urgent care setting, the criterion for a severe asthmatic attack changes from the &lt;50 percent used for decision-making at home to &lt;40 percent), or in whom inhaled short-acting beta agonists do not fully correct the decrement in peak flow [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. In the past, systemic glucocorticoids were commonly withheld for many hours and even days, while treating with bronchodilators and awaiting gradual spontaneous improvement in airway inflammation. Supplemental systemic glucocorticoids should be administered promptly to any patient who develops an asthma exacerbation despite daily or alternate day oral glucocorticoid therapy.",
"   </p>",
"   <p>",
"    In general, the onset of action of systemic glucocorticoids is not clinically apparent until as long as six hours after administration. Thus, the beneficial effect is not likely to be observed during the few hours that the patient spends in the medical office or emergency department [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/30\">",
"     30",
"    </a>",
"    ]. Early administration helps to minimize the delay in improvement anticipated with systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose for systemic glucocorticoids in asthmatic exacerbations remains unknown, although the equivalent of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose of 40 to 60 mg per day in a single or divided dose is typical (",
"    <a class=\"graphic graphic_table graphicRef66549 \" href=\"UTD.htm?0/12/204\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of vomiting, oral administration can be used instead of intravenous administration. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    are rapidly absorbed (peak serum levels achieved at one hour after ingestion) with virtually complete bioavailability, and their efficacy is comparable to intravenous methylprednisolone. Thus, 40 to 60 mg of prednisone administered in a medical office may provide the maximal benefit to be derived from systemic glucocorticoids in acute asthma.",
"   </p>",
"   <p>",
"    Intravenous glucocorticoids should be given to patients who present with impending or actual respiratory arrest, or patients who are intolerant of oral glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. The exact dose of glucocorticoids to use for patients with life-threatening asthma is largely based on expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/32\">",
"     32",
"    </a>",
"    ]. A higher initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    60 to 80 mg every 6 to 12 hours is often chosen for patients who are admitted to the intensive care unit. A lower initial dose of 40 to 60 mg every 12 to 24 hours is likely adequate for patients who are admitted to the hospital, but do not require intensive care. A massive initial dose (eg, methylprednisolone 500 mg intravenous bolus) is no more effective than a large initial dose (125 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transition to oral administration of glucocorticoids can occur when the patient can tolerate and absorb oral medication. When comparable doses are administered, the effect of glucocorticoids by oral and intravenous routes of administration is identical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of a systemic therapy necessary to effect complete resolution of symptoms and return of lung function to baseline varies from patient to patient and attack to attack. As a rough guide, most severe attacks that require hospitalization will resolve (with return of lung function to baseline) in 10 to 14 days. Alternatively, patients can stop their oral glucocorticoids based on resolution of their symptoms and self-monitored peak flow values (eg, when peak expiratory flow is greater than 70 percent of baseline).",
"   </p>",
"   <p>",
"    Tapering oral glucocorticoids is not necessary if the duration of glucocorticoid treatment is less than three weeks (a duration too brief to cause adrenal atrophy) and if inhaled glucocorticoids are concomitantly prescribed for ongoing therapy (to prevent relapse).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Magnesium sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    (2 g infused over 20 min) has bronchodilator activity in acute asthma, possibly due to inhibition of calcium influx into airway smooth muscle cells [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/34\">",
"     34",
"    </a>",
"    ]. Although the routine use of this agent does not seem to confer significant benefit beyond that achieved with the conventional use of beta agonists and systemic glucocorticoids, two systematic reviews concluded that it is helpful in the subgroup of patients with severe attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This agent is suggested for patients who have life-threatening exacerbations or whose exacerbation remains severe (peak expiratory flow &lt;40 percent of baseline) after one hour of intensive conventional therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravenous magnesium has an excellent safety profile; however, it is contraindicated in the presence of renal insufficiency, and hypermagnesemia can result in muscle weakness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=see_link\">",
"     \"Symptoms of hypermagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Nonstandard therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several therapies for acute exacerbations of asthma that may be helpful, but cannot be recommended for routine use at this time, due to insufficient evidence of efficacy. These include the use of helium-oxygen gas mixtures and leukotriene receptor antagonists, which are discussed below, and anesthetic agents (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/45/10967?source=see_link\">",
"     ketamine",
"    </a>",
"    ), nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    , and macrolide antibiotics, which are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H2#H2\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Acute asthma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Helium-oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Helium-oxygen (heliox) mixtures have been administered to patients with asthma in an attempt to decrease work of breathing and improve ventilation. The rationale of this intervention is based on the low density of helium, and the effects of low-density gas inhalation on airflow characteristics. In addition, nebulization of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    using a helium-oxygen gas mixture may increase the mass of albuterol delivered by allowing smaller particles to better penetrate to the lung periphery, compared to nebulization with air or oxygen. The physiology and clinical application of heliox are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=see_link\">",
"     \"Physiology and clinical use of heliox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the theoretical benefits of HeO",
"    <sub>",
"     2",
"    </sub>",
"    , studies have reported conflicting results concerning its efficacy in this setting. Two critical analyses of the published literature found insufficient evidence to recommend the use of helium-oxygen gas mixtures in the treatment of asthmatic attacks [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In part, studies published to date have been small and non-randomized. In addition, it is difficult to exclude with certainty patients who improve due to treatment of their vocal cord (upper airway) dysfunction.",
"   </p>",
"   <p>",
"    At this time, routine use of helium-oxygen mixture cannot be recommended due to conflicting data about its efficacy. However, for patients who have life-threatening exacerbations or whose exacerbation remains severe (peak expiratory flow &lt;40 percent of baseline) after one hour of intensive conventional therapy, heliox-driven",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    nebulization should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Leukotriene receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukotriene receptor antagonists are an established therapy for chronic asthma, but the role of these medications in the management of acute exacerbations is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/40-44\">",
"     40-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of acute administration of an intravenous leukotriene receptor antagonist was assessed in a randomized trial of 201 adults with acute asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/40\">",
"     40",
"    </a>",
"    ]. Patients who had a one-second forced expiratory volume (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) &lt;70 percent predicted following inhalation of nebulized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    were randomly assigned to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    (7 mg or 14 mg IV) or placebo. Montelukast therapy was associated with a 15 percent increase in FEV",
"    <sub>",
"     1",
"    </sub>",
"    at both dosages, compared with a 4 percent increase in patients treated with placebo (",
"    <a class=\"graphic graphic_figure graphicRef78671 \" href=\"UTD.htm?27/10/27822\">",
"     figure 2",
"    </a>",
"    ). However, no intravenous preparation of a leukotriene receptor antagonist is currently available in the United States.",
"   </p>",
"   <p>",
"    A larger randomized trial assessed the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    on 641 adults with acute asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/41\">",
"     41",
"    </a>",
"    ]. Patients treated in the emergency department with a single oral dose of zafirlukast 160 mg (four times the usual total daily dose) were less likely than those receiving placebo to require prolonged observation or hospital admission (10 versus 15 percent, respectively). In addition, patients who received oral zafirlukast 20 mg per day for six days after leaving the emergency department were less likely than patients given placebo to require medical care for relapse during the 28-day follow up period (24 versus 29 percent, respectively).",
"   </p>",
"   <p>",
"    These significant findings are of small magnitude and need to be confirmed in larger trials, but they do offer preliminary evidence that leukotriene receptor blockade could be an effective therapy for acute asthma in adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Ineffective therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of intravenous methylxanthines in addition to beta-agonists, and the use of inhaled glucocorticoids instead of oral or intravenous preparations in the emergency department setting have been shown to be relatively ineffective approaches that cannot be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Methylxanthines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of alternative bronchodilators such as intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    , in addition to beta-agonists, is not recommended in the treatment of acute asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/45\">",
"     45",
"    </a>",
"    ]. These agents are not as potent as the beta agonists when used alone for the treatment of asthma, and provide no further bronchodilation beyond that achieved with inhaled beta agonists alone (",
"    <a class=\"graphic graphic_figure graphicRef63746 \" href=\"UTD.htm?23/46/24301\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. In addition, these agents appear to increase the incidence of adverse effects when combined with bronchodilators [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/47\">",
"     47",
"    </a>",
"    ]. Studies extending over several hours of emergency department care have also failed to show a benefit of theophylline therapy in terms of need for or duration of subsequent hospitalization (",
"    <a class=\"graphic graphic_figure graphicRef72708 \" href=\"UTD.htm?28/27/29117\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/48\">",
"     48",
"    </a>",
"    ]. For patients who are taking oral theophylline at presentation, we typically continue maintenance oral therapy (and check a theophylline blood level); but if oral intake could no longer be continued, we would very rarely use intravenous therapy with aminophylline or theophylline.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some reports have suggested that high dose inhaled glucocorticoids have an effect comparable to oral or intravenous glucocorticoids following initial stabilization in the Emergency Department [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. However, several larger controlled trials and meta-analyses have drawn the opposite conclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/5,53-59\">",
"     5,53-59",
"    </a>",
"    ]. Thus, this approach cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Empiric antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical practice guidelines recommend against empiric antibiotic therapy for the treatment of an asthma exacerbation, because most respiratory infections that trigger an exacerbation of asthma are viral rather than bacterial. However, the trials on which this recommendation is made did not use antibiotics that cover atypical organisms. The use of antibiotics in acute asthma is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=see_link&amp;anchor=H3#H3\">",
"     \"Alternative and experimental agents for the treatment of asthma\", section on 'Empiric antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     DISPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with acute, severe asthmatic exacerbations are at risk for further deterioration in lung function, respiratory failure, and asphyxic death. In many cases, airway obstruction remains labile for days following an acute exacerbation, with wide swings in expiratory flow over minutes or hours. Nocturnal deteriorations are common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Indications for hospitalization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The purpose of hospitalization during an acute exacerbation of asthma is close observation and availability of aggressive interventions in the event of worsening asthma. It also serves to remove the patient from stimuli in the home environment that potentially aggravate asthma, ensure medication compliance, and permit inactivity during recovery from the illness.",
"   </p>",
"   <p>",
"    Identifying patients who should be kept for observation or hospital admission remains largely a matter of clinical judgment. Severe symptoms of coughing, wheezing, and shortness of breath that preclude self-care are obvious indications for continued in-hospital care. Peak flow measurements are also useful for identifying patients \"at risk\" for poor outcomes if discharged home:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A peak expiratory flow less than 40 percent of predicted or of the patient's personal best value at the time of disposition is a reason for continued supervised medical care [",
"      <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients with a peak expiratory flow 40 to 70 percent of predicted, who also demonstrate improving lung function, good asthma self-care skills, and a supportive home environment, can be discharged home [",
"      <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"       3",
"      </a>",
"      ]. Other patients with lung function in the same range may be considered unsafe for discharge. Among the factors favoring continued observation in this group are: new onset asthma, multiple prior hospitalizations or emergency department visits for asthma, use of oral glucocorticoids at the time of presentation with the acute deterioration, and complicating psychosocial difficulties.",
"     </li>",
"     <li>",
"      Most patients with a peak expiratory flow above 70 percent of normal or their personal best can safely continue their care at home [",
"      <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Medications upon discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;An asthmatic attack has not fully resolved even when symptoms have abated. Residual airflow obstruction may last for several days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Oral glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;A short course of oral glucocorticoids significantly reduces the likelihood of a repeat severe exacerbation with emergency department bounce back (\"relapse\") within the succeeding two weeks, and lessens the frequency of persistent severe symptoms evaluated at a two-week telephone follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. As an example, one randomized, controlled trial demonstrating efficacy used an eight day tapering schedule beginning at",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    64",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nearly all patients with a significant asthma exacerbation requiring emergency department evaluation should receive a course of oral glucocorticoids for three to ten days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3\">",
"     3",
"    </a>",
"    ]. For glucocorticoid courses of this duration, there is no need to taper the dose if patients are also taking inhaled glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9817240\">",
"    <span class=\"h3\">",
"     Intramuscular glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular injection of a long-acting glucocorticoid formulation at the time of discharge from the emergency department is occasionally used for patients without access to oral medication or at high risk of medical noncompliance. Intramuscular long-acting glucocorticoid formulations appear to be as effective as oral therapy in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/62-67\">",
"     62-67",
"    </a>",
"    ]. In a randomized trial of 190 adult patients with acute asthma, intramuscular injection of long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (160 mg) resulted in a similarly low rate of relapse as oral methylprednisolone given in a tapering schedule over eight days (total dose = 160 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with regular inhaled glucocorticoids constitutes an important method to prevent recurrent asthma attacks after discontinuation of oral glucocorticoids and to prevent the potential decline in lung function associated with any future severe asthma exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?4/56/5002/abstract/3,31\">",
"     3,31",
"    </a>",
"    ]. Virtually every patient who has suffered an asthma attack severe enough to require urgent care should receive an inhaled glucocorticoid as part of their discharge medication plan (",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Among hospitalized patients, we typically begin (or resume, if previously taking) inhaled glucocorticoids as soon as patients are able to tolerate medication delivery from dry-powder inhalers or metered-dose inhalers (with spacers). Delaying initiation (or reinitiation) of inhaled glucocorticoids until the oral glucocorticoid dose has been reduced to approximately 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or the equivalent is also acceptable, but in our experience this approach more often leads to confusion and medication non-compliance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18909598\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be provided with information about asthma and, if they do not already have one, a personalized action plan (",
"    <a class=\"graphic graphic_form graphicRef55900 \" href=\"UTD.htm?36/39/37498\">",
"     figure 1",
"    </a>",
"    ). Follow-up care with a primary provider should be facilitated whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A table outlining the emergency management of severe asthma exacerbations in adults is provided (",
"    <a class=\"graphic graphic_table graphicRef54125 \" href=\"UTD.htm?32/57/33693\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early recognition and intervention are critical for successful management of asthma exacerbations. The basic principles of care are assessment of attack severity, repeated use of inhaled beta-agonists, early administration of oral or intravenous glucocorticoids, and frequent reassessment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be taught how to measure peak expiratory flow and take appropriate steps upon recognition of increased asthma symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      peak flow decline (",
"      <a class=\"graphic graphic_form graphicRef55900 \" href=\"UTD.htm?36/39/37498\">",
"       figure 1",
"      </a>",
"      ). These include immediate treatment with short-acting inhaled beta agonists, monitoring of medication response, and early self-administration of oral glucocorticoids, when needed (",
"      <a class=\"graphic graphic_algorithm graphicRef56621 \" href=\"UTD.htm?19/23/19829\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the urgent care setting, the severity of an asthma exacerbation is assessed based upon symptoms, physical findings, peak expiratory flow measurements, transcutaneous oximetry, and, in certain circumstances, arterial blood gas measurement. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Severity Assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard regimen for initial care in the emergency department is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      (or an equivalent) 2.5 to 5 mg by continuous flow nebulization every 20 minutes for three doses, then 2.5 to 10 mg every one to four hours as needed. Alternatively, albuterol can be given by MDI with a spacer, 4 puffs every 10 minutes or 8 puffs every 20 minutes for up to four hours, then 4 to 8 puffs every one to four hours as needed. For critically ill patients, some clinicians prefer continuous nebulization, administering 10 to 15 mg over one hour. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Inhaled beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early systemic glucocorticoids should be given to all patients who have a moderate or severe exacerbation, or in whom inhaled short-acting beta agonists do not fully correct the decrement in peak flow. The optimal dose is unknown; however, the equivalent of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose of 40 to 60 mg per day in a single dose or two divided doses is typical for outpatient management. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial dose of systemic glucocorticoids used for the inpatient management of acute asthma exacerbations ranges from",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      60 to 80 mg every 6 to 12 hours for patients in the intensive care unit to 40 to 60 mg every 12 to 24 hours for patients not requiring intensive care, depending on the severity of the asthma exacerbation and the patients response to methylprednisolone during previous exacerbations. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       ipratropium",
"      </a>",
"      may be helpful to patients with severe exacerbations who are in the emergency department, but it does not appear to provide additional benefit to inhaled beta agonists during hospitalization. Adult dosing of ipratropium for nebulization is 500 mcg every 20 minutes for three doses, then as needed. Alternatively, ipratropium can be administered by MDI at a dose of eight inhalations every 20 minutes, then as needed for up to three hours. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Inhaled anticholinergics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A one time infusion of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"       magnesium sulfate",
"      </a>",
"      , 2 grams infused intravenously over 20 minutes, is suggested for patients who have life-threatening exacerbations (ie, impending intubation for respiratory failure) or those whose exacerbation remains severe after one hour of intensive conventional therapy. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Magnesium sulfate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The use of helium-oxygen (heliox) gas mixtures for acute, severe exacerbations may be helpful but is not standard therapy. Intravenous administration of leukotriene receptor antagonists may also be beneficial, although these preparations are not available in the United States. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Nonstandard therapies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend admitting patients who do not respond well after four to six hours of intensive therapy to a setting of high surveillance and care. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Indications for hospitalization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are well enough to go home should be given a brief course of oral glucocorticoids (or an injection of intramuscular glucocorticoids), a prescription for inhaled glucocorticoids, a personalized asthma action plan, and instructions to seek follow up care (",
"      <a class=\"graphic graphic_form graphicRef55900 \" href=\"UTD.htm?36/39/37498\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Disposition'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/1\">",
"      Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest 2004; 125:1081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/2\">",
"      Benatar SR. Fatal asthma. N Engl J Med 1986; 314:423.",
"     </a>",
"    </li>",
"    <li>",
"     National Asthma Education and Prevention Program: Expert Panel Report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD. National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on September 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/4\">",
"      Oborne J, Mortimer K, Hubbard RB, et al. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med 2009; 180:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/5\">",
"      Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/6\">",
"      Brenner BE, Abraham E, Simon RR. Position and diaphoresis in acute asthma. Am J Med 1983; 74:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/7\">",
"      Kelsen SG, Kelsen DP, Fleeger BF, et al. Emergency room assessment and treatment of patients with acute asthma. Adequacy of the conventional approach. Am J Med 1978; 64:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/8\">",
"      McFadden ER Jr, Lyons HA. Arterial-blood gas tension in asthma. N Engl J Med 1968; 278:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/9\">",
"      Martin TG, Elenbaas RM, Pingleton SH. Use of peak expiratory flow rates to eliminate unnecessary arterial blood gases in acute asthma. Ann Emerg Med 1982; 11:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/10\">",
"      Tsai TW, Gallagher EJ, Lombardi G, et al. Guidelines for the selective ordering of admission chest radiography in adult obstructive airway disease. Ann Emerg Med 1993; 22:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/11\">",
"      Findley LJ, Sahn SA. The value of chest roentgenograms in acute asthma in adults. Chest 1981; 80:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/12\">",
"      Zieverink SE, Harper AP, Holden RW, et al. Emergency room radiography of asthma: an efficacy study. Radiology 1982; 145:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/13\">",
"      Aronson S, Gennis P, Kelly D, et al. The value of routine admission chest radiographs in adult asthmatics. Ann Emerg Med 1989; 18:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/14\">",
"      Rossing TH, Fanta CH, Goldstein DH, et al. Emergency therapy of asthma: comparison of the acute effects of parenteral and inhaled sympathomimetics and infused aminophylline. Am Rev Respir Dis 1980; 122:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/15\">",
"      Turner JR, Corkery KJ, Eckman D, et al. Equivalence of continuous flow nebulizer and metered-dose inhaler with reservoir bag for treatment of acute airflow obstruction. Chest 1988; 93:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/16\">",
"      Salzman GA, Steele MT, Pribble JP, et al. Aerosolized metaproterenol in the treatment of asthmatics with severe airflow obstruction. Comparison of two delivery methods. Chest 1989; 95:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/17\">",
"      Idris AH, McDermott MF, Raucci JC, et al. Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. Chest 1993; 103:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/18\">",
"      Newman KB, Milne S, Hamilton C, Hall K. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest 2002; 121:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/19\">",
"      Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987; 82:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/20\">",
"      O'Driscoll BR, Taylor RJ, Horsley MG, et al. Nebulised salbutamol with and without ipratropium bromide in acute airflow obstruction. Lancet 1989; 1:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/21\">",
"      Rodrigo GJ, Rodrigo C. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med 2000; 161:1862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/22\">",
"      Stoodley RG, Aaron SD, Dales RE. The role of ipratropium bromide in the emergency management of acute asthma exacerbation: a metaanalysis of randomized clinical trials. Ann Emerg Med 1999; 34:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/23\">",
"      Rodrigo G, Rodrigo C, Burschtin O. A meta-analysis of the effects of ipratropium bromide in adults with acute asthma. Am J Med 1999; 107:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/24\">",
"      Rodrigo GJ, Rodrigo C. The role of anticholinergics in acute asthma treatment: an evidence-based evaluation. Chest 2002; 121:1977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/25\">",
"      Karpel JP, Schacter EN, Fanta C, et al. A comparison of ipratropium and albuterol vs albuterol alone for the treatment of acute asthma. Chest 1996; 110:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/26\">",
"      McFadden ER Jr, elSanadi N, Strauss L, et al. The influence of parasympatholytics on the resolution of acute attacks of asthma. Am J Med 1997; 102:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/27\">",
"      Garrett JE, Town GI, Rodwell P, Kelly AM. Nebulized salbutamol with and without ipratropium bromide in the treatment of acute asthma. J Allergy Clin Immunol 1997; 100:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/28\">",
"      Fanta CH, Rossing TH, McFadden ER Jr. Emergency room of treatment of asthma. Relationships among therapeutic combinations, severity of obstruction and time course of response. Am J Med 1982; 72:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/29\">",
"      Fanta CH, Rossing TH, McFadden ER Jr. Glucocorticoids in acute asthma. A critical controlled trial. Am J Med 1983; 74:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/30\">",
"      Stein LM, Cole RP. Early administration of corticosteroids in emergency room treatment of acute asthma. Ann Intern Med 1990; 112:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/31\">",
"      Lougheed MD, Garvey N, Chapman KR, et al. Variations and gaps in management of acute asthma in Ontario emergency departments. Chest 2009; 135:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/32\">",
"      McFadden ER Jr. Acute severe asthma. Am J Respir Crit Care Med 2003; 168:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/33\">",
"      Emerman CL, Cydulka RK. A randomized comparison of 100-mg vs 500-mg dose of methylprednisolone in the treatment of acute asthma. Chest 1995; 107:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/34\">",
"      Skobeloff EM, Spivey WH, McNamara RM, Greenspon L. Intravenous magnesium sulfate for the treatment of acute asthma in the emergency department. JAMA 1989; 262:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/35\">",
"      Green SM, Rothrock SG. Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Ann Emerg Med 1992; 21:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/36\">",
"      Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Ann Emerg Med 2000; 36:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/37\">",
"      Rowe BH, Bretzlaff JA, Bourdon C, et al. Intravenous magnesium sulfate treatment for acute asthma in the emergency department: a systematic review of the literature. Ann Emerg Med 2000; 36:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/38\">",
"      Reuben AD, Harris AR. Heliox for asthma in the emergency department: a review of the literature. Emerg Med J 2004; 21:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/39\">",
"      Rodrigo G, Pollack C, Rodrigo C, Rowe BH. Heliox for nonintubated acute asthma patients. Cochrane Database Syst Rev 2003; :CD002884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/40\">",
"      Camargo CA Jr, Smithline HA, Malice MP, et al. A randomized controlled trial of intravenous montelukast in acute asthma. Am J Respir Crit Care Med 2003; 167:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/41\">",
"      Silverman RA, Nowak RM, Korenblat PE, et al. Zafirlukast treatment for acute asthma: evaluation in a randomized, double-blind, multicenter trial. Chest 2004; 126:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/42\">",
"      Camargo CA Jr, Gurner DM, Smithline HA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol 2010; 125:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/43\">",
"      Ramsay CF, Pearson D, Mildenhall S, Wilson AM. Oral montelukast in acute asthma exacerbations: a randomised, double-blind, placebo-controlled trial. Thorax 2011; 66:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/44\">",
"      Watts K, Chavasse RJ. Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database Syst Rev 2012; 5:CD006100.",
"     </a>",
"    </li>",
"    <li>",
"     Nair P, Milan SJ, Rowe BH. Addition of intravenous aminophylline to inhaled beta2-agonists in adults with acute asthma. Cochrane Database Sys Rev; :CD002742",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/46\">",
"      Appel D, Shim C. Comparative effect of epinephrine and aminophylline in the treatment of asthma. Lung 1981; 159:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/47\">",
"      Siegel D, Sheppard D, Gelb A, Weinberg PF. Aminophylline increases the toxicity but not the efficacy of an inhaled beta-adrenergic agonist in the treatment of acute exacerbations of asthma. Am Rev Respir Dis 1985; 132:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/48\">",
"      DiGiulio GA, Kercsmar CM, Krug SE, et al. Hospital treatment of asthma: lack of benefit from theophylline given in addition to nebulized albuterol and intravenously administered corticosteroid. J Pediatr 1993; 122:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/49\">",
"      Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. Am J Respir Crit Care Med 2005; 171:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/50\">",
"      Nuholu Y, Bah&ccedil;eciler NN, Barlan IB, M&uuml;jdat Baaran M. The effectiveness of high-dose inhaled budesonide therapy in the treatment of acute asthma exacerbations in children. Ann Allergy Asthma Immunol 2001; 86:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/51\">",
"      FitzGerald JM, Shragge D, Haddon J, et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J 2000; 7:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/52\">",
"      Edmonds ML, Camargo CA Jr, Brenner BE, Rowe BH. Replacement of oral corticosteroids with inhaled corticosteroids in the treatment of acute asthma following emergency department discharge: a meta-analysis. Chest 2002; 121:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/53\">",
"      FitzGerald JM, Becker A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/54\">",
"      Brenner BE, Chavda KK, Camargo CA Jr. Randomized trial of inhaled flunisolide versus placebo among asthmatic patients discharged from the emergency department. Ann Emerg Med 2000; 36:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/55\">",
"      Schuh S, Reisman J, Alshehri M, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. N Engl J Med 2000; 343:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/56\">",
"      Edmonds ML, Camargo CA, Pollack CV, Rowe BH. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev 2001; :CD002308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/57\">",
"      Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH. The effectiveness of inhaled corticosteroids in the emergency department treatment of acute asthma: a meta-analysis. Ann Emerg Med 2002; 40:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/58\">",
"      Nakanishi AK, Klasner AK, Rubin BK. A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children. Chest 2003; 124:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/59\">",
"      Quon BS, Fitzgerald JM, Lemi&egrave;re C, et al. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev 2010; :CD007524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/60\">",
"      Fiel SB, Swartz MA, Glanz K, Francis ME. Efficacy of short-term corticosteroid therapy in outpatient treatment of acute bronchial asthma. Am J Med 1983; 75:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/61\">",
"      Chapman KR, Verbeek PR, White JG, Rebuck AS. Effect of a short course of prednisone in the prevention of early relapse after the emergency room treatment of acute asthma. N Engl J Med 1991; 324:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/62\">",
"      Lahn M, Bijur P, Gallagher EJ. Randomized clinical trial of intramuscular vs oral methylprednisolone in the treatment of asthma exacerbations following discharge from an emergency department. Chest 2004; 126:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/63\">",
"      Chan JS, Cowie RL, Lazarenko GC, et al. Comparison of intramuscular betamethasone and oral prednisone in the prevention of relapse of acute asthma. Can Respir J 2001; 8:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/64\">",
"      Schuckman H, DeJulius DP, Blanda M, et al. Comparison of intramuscular triamcinolone and oral prednisone in the outpatient treatment of acute asthma: a randomized controlled trial. Ann Emerg Med 1998; 31:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/65\">",
"      McNamara RM, Rubin JM. Intramuscular methylprednisolone acetate for the prevention of relapse in acute asthma. Ann Emerg Med 1993; 22:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/66\">",
"      Hoffman IB, Fiel SB. Oral vs repository corticosteroid therapy in acute asthma. Chest 1988; 93:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/56/5002/abstract/67\">",
"      Ljunghall S, Jakobsson S, Joborn C, et al. Longitudinal studies of mild primary hyperparathyroidism. J Bone Miner Res 1991; 6 Suppl 2:S111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 528 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_5002=[""].join("\n");
var outline_f4_56_5002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Detecting the onset of an exacerbation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Good response to initial home treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Incomplete response to initial home treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Poor response to initial home treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SEVERITY ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Peak flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Gas exchange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Assessing hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Inhaled beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Nebulizer versus MDI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Inhaled anticholinergics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Magnesium sulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Nonstandard therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Helium-oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Leukotriene receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Ineffective therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Methylxanthines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Empiric antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      DISPOSITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Indications for hospitalization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Medications upon discharge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Oral glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9817240\">",
"      - Intramuscular glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18909598\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/528\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/528|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?19/23/19829\" title=\"algorithm 1\">",
"      Home treatment of acute asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/62/26600\" title=\"algorithm 2\">",
"      Emergency Rx severe asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/528|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/10/27822\" title=\"figure 2\">",
"      Montelukast in acute asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/46/24301\" title=\"figure 3\">",
"      Aminophylline B agonist asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29117\" title=\"figure 4\">",
"      Theophylline effect in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/528|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?36/39/37498\" title=\"figure 1\">",
"      Asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/528|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/57/33693\" title=\"table 1\">",
"      Severe asthma exacerbation in adults rapid overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/12/36044\" title=\"table 2A\">",
"      PEFR in men",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/17/36124\" title=\"table 2B\">",
"      PEFR in women",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/12/1229\" title=\"table 2C\">",
"      PEFR in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/12/204\" title=\"table 3\">",
"      Usual doses oral gc asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15934\" title=\"table 4\">",
"      Inhaled GC doses for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20870?source=related_link\">",
"      Anticholinergic agents in the management of acute exacerbations of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10535?source=related_link\">",
"      Invasive mechanical ventilation in adults with acute exacerbations of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30568?source=related_link\">",
"      Physiology and clinical use of heliox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/9/32914?source=related_link\">",
"      Symptoms of hypermagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_56_5003="LD definition IDEA";
var content_f4_56_5003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Individuals with Disabilities Education Act (IDEA), 1997 definition of specific learning disability",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        \"The term 'specific learning disability' means those",
"children who have a disorder in one or more of the basic psychological",
"processes involved in understanding or in using language, spoken or",
"written, which disorder may manifest itself in imperfect ability to",
"listen, think, speak, read, write, spell, or to do mathematical",
"calculations. The term includes such conditions as perceptual",
"handicaps, brain injury, minimal brain dysfunction, dyslexia, and",
"developmental aphasia. The term does not include a learning problem",
"which is primarily the result of visual, hearing, or motor handicaps,",
"of mental retardation, of emotional disturbance, or of environmental,",
"cultural, or economic disadvantage.\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Public Law 94-142 (Federal Register, December 29, 1977, p.65083, 121a.5 and IDEA amendments of 1997, P.L. 105-17, June 4, 1997, 11 stat 37).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_5003=[""].join("\n");
var outline_f4_56_5003=null;
var title_f4_56_5004="Therapies for MG";
var content_f4_56_5004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used therapies for myasthenia gravis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to onset of effect*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to maximal effect*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Symptomatic therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pyridostigmine",
"       </td>",
"       <td>",
"        10 to 15 minutes",
"       </td>",
"       <td>",
"        2 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Chronic immunotherapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Prednisone",
"       </td>",
"       <td>",
"        2 to 3 weeks",
"       </td>",
"       <td>",
"        5 to 6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azathioprine",
"       </td>",
"       <td>",
"        ~12 months",
"       </td>",
"       <td>",
"        1 to 2 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycophenolate mofetil",
"       </td>",
"       <td>",
"        6 to 12 months",
"       </td>",
"       <td>",
"        1 to 2 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclosporine",
"       </td>",
"       <td>",
"        ~6 months",
"       </td>",
"       <td>",
"        ~12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Rapid immunotherapies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Plasmapheresis",
"       </td>",
"       <td>",
"        1 to 7 days",
"       </td>",
"       <td>",
"        1 to 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Intravenous immune globulin",
"       </td>",
"       <td>",
"        1 to 2 weeks",
"       </td>",
"       <td>",
"        1 to 3 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thymectomy",
"       </td>",
"       <td>",
"        1 to 10 years",
"       </td>",
"       <td>",
"        1 to 10 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Estimated times are rough guidelines based upon clinical experience in myasthenia gravis.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_5004=[""].join("\n");
var outline_f4_56_5004=null;
var title_f4_56_5005="CTA false pos intracran aneurys";
var content_f4_56_5005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F69728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F69728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    False-positive intracranial aneurysms reported by CTA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 293px; background-image: url(data:image/gif;base64,R0lGODlh3QElAcQAAP///wAz/4CAgAAZfwAAAEBAQMDAwFBQUCAgIDAwMKCgoPDw8HBwcBAQELCwsODg4NDQ0JCQkGBgYAAMPwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADdASUBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PMwYCk5STBpCYmZotkpWTBQKboqOkJZOlqKmQp6qtroasr7KzfLG0t7hytrm8vWi7vsHCXsDDxsdUxcjLzErKzdDRQM/S1dY21Nfa2yzZKJ2e4eLjApfc56LeJwITA+7v8PHy8hOh6PeY6iYCAwH+/wADChQ4wB6+g4z0meo3sKFDfwURSlSkkAS/hxgJGpzIcVDFERczigwQsaPJQB9F/4QcibHkyZe1Nr5YydKhS5g476QEQLPmwJs5g+qS6aKnz4BAhSpts9Po0X9Jl0r9RbSF06ckq07disQAhBEPIgiIsCBGU4ZYkWrlyjYIBAEECowoQKBuArNrVVx9GrWtXx90445wsGABAgLmiuZNsfdo37+QdRgQXOLwAxhn02qMzNnHZLkkIhBggHdGY5+PO6uO8ZkEAwISVICrBMo0Ws0QF6/erQKC6AQGyh4ggMDSN3G1ZZyumZq38xOB616qS123Rev7buNu/rz7j8y4oWL3Th4H+PBZy6sXcj489/XwlY+3qF3z+/j4rc4HWT/t/fwAotDedvsFaCBPBfLUH/9W/x144ID2JeggfhD6J+GE8FXI4IWRkOOhh4lhyIyGfHGoXDvzpKiiO/WICA2Jjplo1oIlutgMjKjJiBmNMdo4YoLLsdSgeTzm6OMyODKn40xFKnkkMkkKuWRRTUr55DFRjjTkDUFqOeWVqwBZpZdIdCnSlmCWkuWZX3YzJptpCrNmRmjWYCadbca5yJwt5anXm3jq6QufD9VJw519CtoLoTb5yRigiSqaC6MNGWoberlJOqmYmKZ3BKKFOqqpR5xiaqlykIY6aiqzUZLcjJ2eCqupoq6KR6uflIqerDvGWqutflD6068L+QqsLMJu9mmqjR77SrJqlclspcQ6mwf/tADxyqSx1qqCrXjSctstKt9muqy445JSrqdGgNpsumrq6l61/KEL7ybrakulvfdmki+9Kk07bL+j/BsurQSnIy+BB+8KcMJMLRxhw/NCrInB5yJscT4SW0gxwxuHeanG7QqsbMiOYFwyvygnonIR7lLbcsodb/jxxDMnVHONGTucs84j+9xzxT9TtHOPQ4NcNCIvExHzwEszfbSRSeMcNRwLKDBWWZhN7WTVHl/9xgIJxEVAA1wrFjTRK5MsNhuT3UVXiN14bSXYNr/dBtkEJIBAbMeF82qvbjttcrR6s7GABA0clkDaJeAqwODbFj7E0ycnnoZooQw3X9OXH57t/8OaD6FA3waUrUDXaysNs+jglq4GAw0Qtx/o7MFuruzB2k0m3jzz3gfuQWCOuPAxtW716ywjbwfx0+jOrvPX+g4n8EhTX73yYbcttPZ4QP+d9PqCT4z1gWJPtfnPox+p92yzT4f4Phg/uvztc583/K7jHwf9PbBf7Pw3FP0Fj3mWI2DEDJg9BH5PgW8AIA8EuDsIukGCO6Dg9CzIBgzqQIPl4+AUPJgDEJJOhDBzn6rU9zUUroGERGqeC8kAQy6R74QzLJ4K38W/5eXQDDXExg1/mIYg2mmIRDyDEQ+FxCR2QXKU21cCi9dEJ24BijuUGQvvZsUxLJGB6+tiGL6IKv8ZilELZJzVA894PjC20IHxY2MX0ki4NcpxC3SsnB3vmIU8SnGPfLyCH61SxUD2MYtQ62H3DHlIN3IRjv1jpBUG6SYzShIKlFyBCS/ZyDJOMXqW5GQTMvmnUIpyCaR8lClPmYRUCqiQrMQkIjNnuFXGsl2zPB4kfXhLJ7hyHbDsJRN+mR1bCpM9ubzfFn93TF8mc4C7XGQzbwABA1yGdZ4EJCg/OU0YQKB2t3tmBWvJzW66oGwECKcjmRnN/R1Bch/6EN30JoAGvEad2Yxj6Iz5QRSt6J/waFHpIEAAB8BlLVhc5/UU6U6GHpCe1KmLVhKaz0jmjp8lDObVHmAAA0j/ADbXVFtFeXnRco4Poyg7aGlGKs19mrR+GoUgMYv10gDGVIEzpQ9KbbhT5OW0XjWd4E0J+NOA9fSIR+VdURWUVIWmb4ZL3WQrh+q/qFIVpk0tnVWzqkZ9cnCrQc3gVeUHVm1SkauciKdaKzHPB4lzgy416zblOkF/AhSgAhVRWb0aV76eNKzl2atF+zrYv9I1PoIlKWEVa1i/AiixLSXnYT841vVAtqHtfGhJJ2vZt4ZQk5UVK1orCVjyXFazknWsTUcbmdM20KGv3axqKeTZh0n1ZpGd62wRW1vcYja1hcVqab3j2jDC1riyDW5+ivvG4zY3uYx9bG+XuVDqPhW4/9Fd7nSd+0jusnOxufXMWsfbVllQtKvKXe1webpep77vcna964ryiovz1nG3om0vUvWL3uzml7PI2m5mY4vd8AoXwEJkLcfcu0LvVtfB1wXvbxub3lswt7sDRu5Z+atH/M7iwt/N8HM3jOD9lrgVIH6wiDFMYg+z98TeEnCBJwxdA6sXxiylMS9SHOEVh7jFFc6ogkWWY9QC2b8HdvGLlWxiJqNYxhI2co11fGMnM5iHxuDxeyG85SlLucpB/jCUvUzgKJeZwkgWMocLNuYj2xjNb/6vlYt85h23WbdhlnOel7znJvf5yVfWIpcbbN0uu5nKek6zmAOdSB+reMZfBv+zovk86WfdGc6ITvKfmThkYHaaZoympZk1POoR47nSfkY1oOlM6lPHWdKvVjOO+xvrAIdal5Cus6szTdlP03TW8bq1MgeNZWILOtethjWvF81qU+860piGdqJrneA1K0zY0ES2sw8t7V5bm7TADkTWBKAAyOkH2+MsNYvV/eNn63ray05E2ehyF2zSOt4x/HaHN41uuLo72Y1wAAEOAIDhOMDe9+V3vz8L7jk3e92aVjUhVKrSmVw64tSWtcPv3e18h/sPFE8nwvctcU7r+48bT3jJOf7uRYiGNK+JQOA8UQBQjNdV8ZVviiZg85v7nOY51zk9ev7zon8i6EIPKNH/jT7eAiA96SxaOtPj6XSoq4jnU8+61n9e3hs8gDgGsMzMt072spv97GhPu9rXzva2u/3tWe/6DRRwGASszpx4z7ve9873vvv974APvOAHT/jCG/7wiE+84hfP+MY7/vGQj7zkJ0/5ylv+8tQLy9bI4BtymxsM1QwpFzpKejGMG4c1WADpO/p5SESn3mKIKGjE8E2ReyGiBAhD7QuAADBMJqJyZwRhDIOYMazu67kfAzpRPwPpdDQMh/lKGFRvgNMRQPSiEPsYDHBPL9rT9l2oSwEOEPwqEBQBhyG4GD4KOFK8vAwKoAtpdF/QinfhAAL4aAOwr4W4pY4Ad/cFyMd//5nwGu1XBnMzRrjHfDSQgF5AUHJhf17AfqUwHMVRDmKQOgLwGtcXBhzlUSD1RAmQf2fTellwGA5QNuVHBb9HgJiwgGLwAOiEAAdHQ+C3BTJoF9L3BRBQNg0QgF4gf5g3hERYhEZ4hEiYhEq4hEzYhE74hFAYhVI4hVRYhVZ4hVj4HKtngkNQAPNnfAWwg0uIezWYA3TRApSxfQLggkZYFwBwOqBhAAfghWWhNQZQABLANREwfjVIbm8Rdul0CXJIhyqBh2koAgxQcxLwFVrjAAdwANI3iAxQFuSmEqujNWHxFscnAAfniHh4CeQ2OQoAAY9obp4oAR21hg9QCauzAP+TcwBlWAKr6AASEIYO4IUiIAmOeACuWABAiHduKBqxIXAH8BoERxcSYIwA8BoMYHAAcDZ1oQC144vEqIzGCBezJwLFQTu9RxcIUDa9V40D94ygIRh0UTth1wAAIBoKcDr4h3/P2De1842wQQLuKAD4BxdeUXPpBwAJ0AACUDZiOAK/d47oB4A8cTY++I8dqHcR9TgFl04CcBgAcIb+mHsNcBcLMI59MxfJ5zkTiZG9R46Rk4i1U5HJVzYROQkUSRnmSABcAxcpqI6/UYkkqY8kOQI1uTo4CQAPkJELAIEkWBWTEQpnWJQJOR0RWHwOORrEURZ0UQkoKQJn6JJykYb/FhmVlJCTh0iMKZh7WQmWEnkKVjmVIvB1ZTN/k1MXpCEYOHmIPBEYDICTZIMAZfEZlNBWSHmUIveWS7mCrOSGdEFwokF+tIiSBlCYEWlQBCBzWFlQvjFwBnCYdOEAcGgR6eQAFBmW6yiZh1k7DPBRcmGRVFkXXxEBDFB9HPmXOSkCqKma+IcYfBMBXgEADfCDiTmKN7iXuYeUfpmUe+eGP4mQITmO3hgXZbEAw2FPIpCGDlA7MlecBAcBh0EX2cg3B2mWFimdb3ibrzGayScCp1NvmlkXvHiTxdeVhzFwrogYvyd+AECKdUGDoiF6vAkAvpmerIl4pFkGr/GLR3AALweYhP1JBrfJhUNwAGyYhQzaoA76oBAaoRI6oRRaoRZ6oRiaoRq6oRzaoR5qQSEAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bars represent the number of reported aneurysms of each size from 199 false-positive reports of aneurysms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: van Gelder, JM. Computed tomographic angiography for detecting cerebral aneurysms: implications of aneurysm size distribution for the sensitivity, specificity, and likelihood ratios. Neurosurgery 2003; 53:597.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_5005=[""].join("\n");
var outline_f4_56_5005=null;
var title_f4_56_5006="Scheme for classifying RCM";
var content_f4_56_5006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 475px\">",
"   <div class=\"ttl\">",
"    A scheme for classifying radiocontrast media",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 455px; height: 261px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_5006=[""].join("\n");
var outline_f4_56_5006=null;
var title_f4_56_5007="Lymphomatous uveitis";
var content_f4_56_5007=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55813&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lymphomatous uveitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 402px; height: 322px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chorioretinal infiltrates froma patient with a primary lymphoma of the central nervous system.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James T Rosenbaum.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_56_5007=[""].join("\n");
var outline_f4_56_5007=null;
